Questions and Replies

Reply:

1. The bridge in question may be one of the bridges on the unproclaimed roads, meaning that it is neither registered on the provincial road asset nor municipal road asset.

Since the recent floods, the Mpumalanga provincial government embarked on a programme to conduct an assessment to determine the extent of damage to infrastructure in the area of Bushbuckridge.

As a response to the damages caused by floods, the province and municipality agreed on a joint programme through a municipal support programme whereby a monthly activity such as grading, backfill and re-gravel are being undertaken on the affected roads.

With regard to the affected bridge, the province will be finalising the road and bridge condition assessment which will guide the type of intervention, budget and estimated timelines required.

2. The Department does not have a budget specifically allocated for this bridge, however the province has put aside a budget of R16 million for the maintenance of all bridges across the province.

Reply:

(1) The list of contacted suppliers is available on the National Department of Health’s website, at the following url: https://www.health.gov.za/tenders/

Click on the tab: Master Health Product List.

1. See attached document with list of essential medicines where contracts were awarded to one supplier only on pages 1–21;
2. See attached document with list of essential medicines where contracts were awarded to more than supplier only from page 22 onwards.

(2) The decision to award a contract to one supplier only is informed by a number of factors including the following:

• The product is only available from one supplier registered with SAHPRA (i.e. sole supplier);
• During the contracting process, a bid was only received from one registered supplier even if there are other suppliers in the market;
• The estimated tender volumes are too low to justify award to more than one supplier as this decreases the benefits derived from economies of scale.

(3) It is the standard practice of the Department of Health to award more than one supplier in to manage risks related to supply challenges for certain strategic products that are important for successful implementation of public health programmes.

The decision to award contracts to more than one supplier depends on factors such as the following:

• The estimated tender volumes are high because of high disease burden, as in the case of first line antiretrovirals used in the management of HIV;
• The highest scoring bidder does not have the capacity to meet estimated tender volumes and their inability to meet demand during a contract period would result in a supply challenge;
• There is a risk to public health if the medicine is not available.

END.

Annexure 1

Medicine Description (More than one contracted supplier)

• Abacavir; 20mg/ml; Solution; 240 ml
• Allopurinol; 300mg; Tablet; 30 Tablets
• Amitriptyline; 25mg; Tablet; 28 Tablets
• Amlodipine; 10mg; Tablet; 28 Tablets
• Amlodipine; 5mg; Tablet; 28 Tablets
• Amoxicillin, Clavulanic Acid; 125mg/5ml, 31.25mg/5ml; Suspension; 100 ml
• Amoxicillin, Clavulanic Acid; 250mg, 125mg; Tablet; 15 Tablets
• Amoxicillin, Clavulanic Acid; 250mg/5ml, 62.5mg/5ml; Suspension; 100 ml
• Amoxicillin, Clavulanic Acid; 875mg, 125mg; Tablet; 10 Tablets
• Amoxicillin; 125mg/5ml; Suspension; 100 ml
• Amoxicillin; 250mg/5ml; Suspension; 100 ml
• Amoxicillin; 250mg; Capsule; 15 Capsules
• Amoxicillin; 500mg; Capsule; 15 Capsules
• Ampicillin; 250mg; injection; 1 Injection
• Ampicillin; 500mg; injection; 1 Injection
• Aspirin; 300mg; tablet, scored; 14 Tablets
• Atenolol; 50mg; Tablet; 30 Tablets
• Atorvastatin; 10mg; Tablet; 28 Tablets
• Atropine; 1mg/ml; injection; 1 ml
• Atropine; 500mcg/ml; injection; 1 ml
• Azithromycin; 500mg; Tablet; 2 Tablets
• Azithromycin; 500mg; Tablet; 3 Tablets
• Calcium Carbonate, Glycine; 420mg, 180mg; Tablet; 168 Tablets
• Calcium Carbonate; 500mg; Tablet; 10 Tablets
• Calcium Carbonate; 500mg; Tablet; 30 Tablets
• Carbamazepine; 200mg; Tablet; 56 Tablets
• Carbamazepine; 200mg; Tablet; 84 Tablets
• Cefazolin; 1g; injection; 1 Injection
• Cefazolin; 500mg; injection; 1 Injection
• Ceftriaxone; 1g; injection; 1 Injection
• Ceftriaxone; 250mg; injection; 1 Injection
• Ceftriaxone; 500mg; injection; 1 Injection
• Cetirizine; 10mg; Tablet; 28 Tablets
• Chlorphenamine; 2mg/5ml; Syrup; 50 ml
• Ciprofloxacin; 500mg; Tablet; 10 Tablets
• Citalopram; 20mg; Tablet; 28 Tablets
• Clotrimazole; 1%; Cream; 20 g
• Clotrimazole; 500mg/50g; cream, vaginal; 50 g
• Dexamethasone; 4mg/ml; injection; 1 ml
• Diclofenac; 75mg/3ml; Injection; 3 ml
• Dolutegravir; 50mg; Tablet; 30 Tablets
• Doxazosin; 4mg; Tablet; 30 Tablets
• Doxycycline; 100mg; Tablet; 14 Tablets
• Efavirenz; 200mg; Tablet; 84 Tablets
• Efavirenz; 600mg; Tablet; 28 Tablets
• Enalapril; 10mg; Tablet; 28 Tablets
• Enalapril; 20mg; Tablet; 30 Tablets
• Enalapril; 5mg; Tablet; 28 Tablets
• Epinephrine (Adrenaline); 1mg/ml; injection; 1 ml
• Fentanyl; 100mcg/2ml; injection; 2 ml
• Ferrous Sulfate Co; 170mg; Tablet; 28 Tablets
• Flucloxacillin; 250mg; Capsule; 20 Capsules
• Flucloxacillin; 250mg; Capsule; 40 Capsules
• Fluoxetine; 20mg; Capsule; 28 Capsules
• Folic Acid; 5mg; Tablet; 28 Tablets
• Furosemide; 40mg; Tablet; 28 Tablets
• Furosemide; 40mg; Tablet; 56 Tablets
• Furosemide; 40mg; Tablet; 84 Tablets
• Glibenclamide; 5mg; Tablet; 28 Tablets
• Glibenclamide; 5mg; Tablet; 56 Tablets
• Glimepiride; 1mg; Tablet; 28 Tablets
• Glimepiride; 2mg; Tablet; 28 Tablets
• Glimepiride; 4mg; Tablet; 28 Tablets
• Hydrochlorothiazide; 25mg; Tablet; 28 Tablets
• Hydrocortisone; 100mg/2ml; injection; 2 ml
• Ibuprofen; 200mg; Tablet; 15 Tablets
• Ibuprofen; 200mg; Tablet; 42 Tablets
• Ibuprofen; 200mg; Tablet; 84 Tablets
• Ibuprofen; 400mg; Tablet; 15 Tablets
• Isoniazid; 100mg; Tablet; 28 Tablets
• Isoniazid; 300mg; Tablet; 28 Tablets
• Lamivudine, Abacavir, Dolutegravir; 300mg, 600mg, 50mg; Tablet; 28 Tablets
• Lamivudine, Abacavir; 300mg, 600mg; Tablet; 28 Tablets
• Lamivudine, Abacavir; 60mg, 120mg; Tablet; 28 Tablets
• Lamivudine; 10mg/ml; Solution; 240 ml
• Lamivudine; 150mg; Tablet; 56 Tablets
• Lansoprazole; 30mg; Capsule; 28 Capsules
• Loperamide; 2mg; Tablet; 6 Tablets
• Lopinavir, Ritonavir; 200mg, 50mg; Tablet; 112 Tablets
• Metformin; 500mg; Tablet; 56 Tablets
• Metformin; 500mg; Tablet; 84 Tablets
• Metformin; 850mg; Tablet; 28 Tablets
• Metformin; 850mg; Tablet; 56 Tablets
• Metformin; 850mg; Tablet; 84 Tablets
• Metoclopramide; 10mg; Tablet; 10 Tablets
• Metronidazole; 400mg; Tablet; 14 Tablets
• Metronidazole; 400mg; Tablet; 5 Tablets
• Metronidazole; 500mg/100ml; injection; 100 ml
• Midazolam; 15mg/3ml; injection; 3 ml
• Midazolam; 5mg/5ml; injection; 5 ml
• Morphine; 10mg/ml; injection; 1 ml
• Morphine; 15mg/ml; injection; 1 ml
• Omeprazole; 20mg; Capsule; 14 Capsules
• Oxytocin; 10IU/ml; injection; 1 ml
• Pantoprazole; 20mg; Tablet; 30 Tablets
• Paracetamol; 500mg; Tablet; 100 Tablets
• Paracetamol; 500mg; Tablet; 20 Tablets
• Pethidine; 100mg/2ml; injection; 2 ml
• Pethidine; 50mg/ml; injection; 1 ml
• Prednisone; 5mg; Tablet; 28 Tablets
• Rifampicin, Isoniazid; 150mg, 75mg; Tablet; 56 Tablets
• Rifampicin, Isoniazid; 150mg, 75mg; Tablet; 84 Tablets
• Rifampicin, Isoniazid; 300mg, 150mg; Tablet; 56 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 112 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 56 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 84 Tablets
• Salbutamol; 100mcg; Inhaler; 200 Doses
• Simvastatin; 10mg; Tablet; 28 Tablets
• Simvastatin; 20mg; Tablet; 28 Tablets
• Sodium Chloride; 0.9%; injection; 10 ml
• Spironolactone; 25mg; Tablet; 28 Tablets
• Sulfamethoxazole, Trimethoprim; 200mg/5ml, 40mg/5ml; Suspension; 100 ml
• Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 28 Tablets
• Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 56 Tablets
• Tenofovir, Emtricitabine, Efavirenz; 300mg, 200mg, 600mg; Tablet; 28 Tablets
• Tenofovir, Emtricitabine, Efavirenz; 300mg, 200mg, 600mg; Tablet; 84 Tablets
• Tenofovir, Emtricitabine; 300mg, 200mg; Tablet; 28 Tablets
• Tenofovir, Lamivudine, Dolutegravir; 300mg, 300mg, 50mg; Tablet; 84 Tablets
• Tenofovir, Lamivudine, Dolutegravir; 300mg, 300mg, 50mg; Tablet; 28 Tablets
• Tramadol; 50mg; Capsule; 100 Capsules
• Tramadol; 50mg; Capsule; 20 Capsules
• Vitamin B1 (Thiamine); 100mg; Tablet; 28 Tablets
• Vitamin B6 (Pyridoxine); 25mg; Tablet; 28 Tablets

Annexure 2

Medicine Description (One contracted supplier)

• Abacavir; 300mg; Tablet; 56 Tablets
• Abacavir; 60mg; Tablet, dispersible; 56 Tablets
• Acetazolamide; 250mg; Tablet; 100 Tablets
• Acetazolamide; 250mg; Tablet; 30 Tablets
• Acetic Acid; Liquid; 500 ml
• Acetylcysteine; 200mg/ml; injection; 10 ml
• Acetylcysteine; 200mg; Tablet; 20 Tablets
• Aciclovir; 200mg; Tablet, dispersible; 25 Tablets
• Aciclovir; 250mg; injection; 1 Injection
• Aciclovir; 400mg; Tablet, dispersible; 70 Tablets
• Adenosine; 6mg/2ml; injection; 2 ml
• Albendazole; 400mg; Tablet; 1 Tablet
• Albumin, Human, Normal; 20%; Infusion (parenteral); 100 ml
• Albumin, Human, Normal; 20%; Infusion (parenteral); 50 ml
• Alfentanil; 1mg/2ml; injection; 2 ml
• Allopurinol; 100mg; Tablet; 100 Tablets
• Allopurinol; 100mg; Tablet; 28 Tablets
• Allopurinol; 100mg; Tablet; 56 Tablets
• Alprazolam; 0.5mg; Tablet; 30 Tablets
• Alprostadil; 500mcg/ml; injection; 1 ml
• Alteplase; 50mg; injection; 1 Injection
• Aluminium hydroxide; 300mg/5ml; Suspension; 500 ml
• Amikacin Sulph; 100mg/2ml; injection; 2 ml
• Amikacin Sulph; 250mg/2ml; injection; 2 ml
• Amikacin Sulph; 500mg/2ml; injection; 2 ml
• Aminophylline; 250mg/10ml; injection; 10 ml
• Amiodarone; 150mg/3ml; injection; 3 ml
• Amiodarone; 200mg; Tablet; 30 Tablets
• Amisulpride; 200mg; Tablet; 30 Tablets
• Amisulpride; 50mg; Tablet; 30 Tablets
• Amitriptyline; 10mg; Tablet; 100 Tablets
• Amitriptyline; 10mg; Tablet; 28 Tablets
• Amitriptyline; 25mg; Tablet; 100 Tablets
• Amitriptyline; 25mg; Tablet; 168 Tablets
• Amitriptyline; 25mg; Tablet; 500 Tablets
• Amitriptyline; 25mg; Tablet; 56 Tablets
• Amitriptyline; 25mg; Tablet; 84 Tablets
• Amoxicillin, Clavulanic Acid; 1,000mg, 200mg; injection; 1 Injection
• Amoxicillin, Clavulanic Acid; 500mg, 100mg; injection; 1 Injection
• Amoxicillin/Clavulanic Acid; 600mg/42.9mg; Suspension; 100 ml
• Amoxicillin; 250mg; Capsule; 100 Capsules
• Amoxicillin; 500mg; Capsule; 100 Capsules
• Anastrozole; 1mg; Tablet; 28 Tablets
• Aqueous; Cream; 100 g
• Aqueous; Cream; 500 g
• Aripiprazole; 10mg; Tablet; 30 Tablets
• Aripiprazole; 15mg; Tablet; 30 Tablets
• Aripiprazole; 5mg; Tablet; 30 Tablets
• Artemether, Lumefantrine; 20mg, 120mg; Tablet; 24 Tablets
• Artesunate; 60mg; injection; 1 Injection
• Aspirin; 300mg; Tablet; 96 Tablets
• Atazanavir, Ritonavir; 300mg, 100mg; Tablet; 28 Tablets
• Atazanavir; 200mg; Capsule; 60 Capsules
• Atazanavir; 300mg; Capsule; 30 Capsules
• Atenolol; 100mg; Tablet; 28 Tablets
• Atenolol; 25mg; Tablet; 28 Tablets
• Atorvastatin; 20mg; Tablet; 30 Tablets
• Atorvastatin; 40mg; Tablet; 30 Tablets
• Atracurium; 25mg/2.5ml; injection; 2.5 ml
• Atracurium; 50mg/5ml; injection; 5 ml
• Atropine; 1%; Drop, Eye; 5 ml
• Azathioprine; 50mg; Tablet; 100 Tablets
• Balanced Salt; solution, ophthalmic; 15 ml
• Balanced Salt; solution, ophthalmic; 500 ml
• Barium Sulfate With Suspending Agent; 4.6%; Suspension; 225 ml
• Barium Sulfate With Suspending Agent; 98g/100g; Powder; 340 g
• Barium Sulfate; BP; Suspension; 1 Kit
• Beclometasone; 100mcg; Inhaler; 200 Doses
• Beclometasone; 100mcg; Inhaler; SERIES; 200 Doses
• Beclometasone; 200mcg; Inhaler; 200 Doses
• Beclometasone; 50mcg; Inhaler; 200 Doses
• Beclometasone; 50mcg; Inhaler; SERIES; 200 Doses
• Beclometasone; 50mcg; Spray, Nasal; 150 Doses
• Benzoin Co; Tincture; 100 ml
• Benzoin Co; Tincture; 20 ml
• Benzydamine, Chlorhexidine; 22.5mg/15ml, 18mg/15ml; Mouthwash; 200 ml
• Benzyl Benzoate; 25%; Liquid; 100 ml
• Betamethasone Disodium Phosphate; 4mg/ml; injection; 1 ml
• Betamethasone Valerate; 0.1%; Cream; 15 g
• Betamethasone Valerate; 0.1%; Cream; 50 g
• Betamethasone Valerate; 0.1%; Cream; 500 g
• Betamethasone; 500mcg; Tablet; 100 Tablets
• Betamethasone; 500mcg; Tablet; 20 Tablets
• Betaxolol; 2.5mg/ml; Drop, Eye; 5 ml
• Betaxolol; 5mg/ml; Drop, Eye; 5 ml
• Bevacizumab; 100mg/4ml; injection; 4 ml
• Bezafibrate; 400mg; Tablet; 30 Tablets
• Bimatoprost; 0.3mg/ml; Drop, Eye; 3 ml
• Biperiden; 2mg; Tablet; 100 Tablets
• Biperiden; 5mg/ml; injection; 1 ml
• Bisacodyl; 10mg; Suppository; 10 Suppositories
• Bleomycin; 15IU; injection; 1 Injection
• Bortezomib; 3.5mg; injection; 10 ml
• Botulinum Toxin, Type A, Lyophilised; 100IU; injection; 1 Injection
• Brimonidine; 1.5mg/ml; Drop, Eye; 5 ml
• Brimonidine; 2mg/ml; Drop, Eye; 5 ml
• Bromocriptine; 2.5mg; Tablet; 30 Tablets
• Budesonide, Formoterol; 160mcg, 4.5mcg; Inhaler; 60 Doses
• Budesonide, Formoterol; 320mcg, 9mcg; Inhaler; 60 Doses
• Bupivacaine, Adrenaline; 5mg/ml, 5mcg/ml; injection; 20 ml
• Bupivacaine, Dextrose; 5mg, 72.7mg; injection; 4 ml
• Bupivacaine; 5mg/ml; injection (Spinal); 10 ml
• Bupivacaine; 5mg/ml; injection (Spinal); 4 ml
• Busulfan; 2mg; Tablet; 100 Tablets
• Caffeine; 20mg/ml; injection; 1 ml
• Calamine; Lotion; 100 ml
• Calcium Folinate; 100mg; injection; 1 Injection
• Calcium Folinate; 15mg; Tablet; 10 Tablets
• Calcium Folinate; 300mg; injection; 1 Injection
• Calcium Gluconate; 10%; injection; 10 ml
• Capecitabine; 150mg; Tablet; 60 Tablets
• Capecitabine; 500mg; Tablet; 120 Tablets
• Captopril; 25mg; Tablet; 60 Tablets
• Carbamazepine; 100mg/5ml; Suspension; 250 ml
• Carbamazepine; 200mg; Tablet; 100 Tablets
• Carbamazepine; 200mg; Tablet; 28 Tablets
• Carbimazole; 5mg; Tablet; 100 Tablets
• Carboplatin; 150mg/15ml; injection; 15 ml
• Carboplatin; 450mg/45ml; injection; 45 ml
• Carvedilol; 12.5mg; Tablet; 28 Tablets
• Carvedilol; 25mg; Tablet; 30 Tablets
• Cefalexin; 125mg/5ml; Suspension; 100 ml
• Cefalexin; 250mg/5ml; Suspension; 100 ml
• Cefalexin; 250mg; Capsule; 20 Capsules
• Cefalexin; 500mg; Capsule; 20 Capsules
• Cefepime; 1g; injection; 1 Injection
• Cefepime; 2g; injection; 1 Injection
• Cefotaxime; 1g; injection; 1 Injection
• Cefotaxime; 500mg; injection; 1 Injection
• Ceftazidime; 1g; injection; 1 Injection
• Ceftazidime; 2g; injection; 1 Injection
• Cetirizine; 1mg/ml; Syrup; 150 ml
• Chlorambucil; 2mg; Tablet; 25 Tablets
• Chloramphenicol; 0.5%; Drop, Eye; 10 ml
• Chloramphenicol; 1%; ointment, eye; 3.5 g
• Chlorhexidine, Alcohol; 0.5%, 70%; Solution (without emolient); 500 ml
• Chlorhexidine, Alcohol; 0.5%, 70%; Solution; 50 ml
• Chlorhexidine; 0.2%; Mouthwash; 200 ml
• Chlorhexidine; 4%; Solution (Hibiscrub); 500 ml
• Chlorphenamine; 4mg; Tablet; 10 Tablets
• Chlorphenamine; 4mg; Tablet; 30 Tablets
• Chlorpromazine; 100mg; Tablet; 56 Tablets
• Chlorpromazine; 25mg; Tablet; 56 Tablets
• Ciclosporin; 100mg/ml; Solution; 50 ml
• Ciclosporin; 100mg; Capsule; 50 Capsules
• Ciclosporin; 25mg; Capsule; 50 Capsules
• Ciclosporin; 50mg; injection; 1 Injection
• Ciprofloxacin; 100mg/50ml; injection; 100 ml
• Ciprofloxacin; 250mg/5ml; Suspension; 100 ml
• Ciprofloxacin; 250mg; Tablet; 10 Tablets
• Ciprofloxacin; 3mg/ml; Drop, Eye; 5 ml
• Ciprofloxacin; 400mg/200ml; Infusion (parenteral); 200 ml
• Cisatracurium; 10mg/5ml; injection; 5 ml
• Cisatracurium; 5mg/2.5ml; injection; 2.5 ml
• Cisplatin; 10mg/10ml; injection; 10 ml
• Cisplatin; 50mg/50ml; injection; 50 ml
• Citalopram; 10mg; Tablet; 30 Tablets
• Clarithromycin; 125mg/5ml; Suspension; 60 ml
• Clarithromycin; 250mg/5ml; Suspension; 60 ml
• Clarithromycin; 500mg; Tablet; 14 Tablets
• Clindamycin; 150mg; Capsule; 100 Capsules
• Clindamycin; 150mg; Capsule; 20 Capsules
• Clindamycin; 600mg/4ml; injection; 4 ml
• Clobetasol; 0.05%; Cream; 25 g
• Clobetasol; 0.05%; Ointment; 25 g
• Clomifene; 50mg; Tablet; 10 Tablets
• Clomipramine; 25mg; Tablet; 50 Tablets
• Clonazepam; 0.5mg; Tablet; 84 Tablets
• Clonazepam; 2mg; Tablet; 84 Tablets
• Clopidogrel; 75mg; Tablet; 30 Tablets
• Clotiapine; 40mg/4ml; injection; 4 ml
• Clotrimazole; 500mg; Pessary; 1 Pessary
• Cloxacillin; 250mg; injection; 1 Injection
• Cloxacillin; 500mg; injection; 1 Injection
• Clozapine; 100mg; Tablet; 100 Tablets
• Clozapine; 25mg; Tablet; 100 Tablets
• Coal Tar; BP; Solution; 500 ml
• Codeine Phosphate; 30mg; Tablet; 100 Tablets
• Colchicine; 500mcg; Tablet; 12 Tablets
• Cyclopentolate, Phenylephrine; 0.2%, 1%; Drop, Eye; 5 ml
• Cyclopentolate; 1%; Drop, Eye; 15 ml
• Cyclophosphamide; 1g; injection; 1 Injection
• Cyclophosphamide; 500mg; injection; 1 Injection
• Cyclophosphamide; 50mg; Tablet; 50 Tablets
• Cyproterone, Ethinylestradiol; 2mg, 0.035mg; Tablet; 28 Tablets
• Cyproterone; 10mg; Tablet; 15 Tablets
• Cyproterone; 50mg; Tablet; 20 Tablets
• Dacarbazine; 200mg; injection; 1 Injection
• Dapsone; 100mg; Tablet; 100 Tablets
• Darunavir, Ritonavir; 400mg, 50mg; Tablet; 56 Tablets
• Deferasirox; 250mg; Tablet; 28 Tablets
• Deferasirox; 500mg; Tablet; 28 Tablets
• Deferoxamine; 500mg; injection; 1 Injection
• Desmopressin; 0.1mg; Tablet; 30 Tablets
• Desmopressin; 0.2mg; Tablet; 30 Tablets
• Desmopressin; 100mcg/ml; Spray, Nasal; 5 ml
• Desmopressin; 4mcg/ml; injection; 1 Injection
• Dexamethasone; 0.1%; Drop, Eye; 5 ml
• Dextrose In Water; 50%; injection; 20 ml
• Dextrose In Water; 50%; injection; 50 ml
• Dextrose Monohydrate; BP; Powder; 500 g
• Dextrose Monohydrate; BP; Powder; 75 g
• Dextrose, Electrolyte; 5%; Infusion (parenteral); 1 L
• Dextrose, Maintelyte; 10%; Infusion (parenteral); 1 L
• Dextrose, Maintelyte; 5%; Infusion (parenteral); 1 L
• Dextrose; 10%; Infusion (parenteral); 1 L
• Dextrose; 5%; Infusion (parenteral); 1 L
• Dextrose; 5%; Infusion (parenteral); 100 ml
• Dextrose; 5%; Infusion (parenteral); 200 ml
• Dextrose; 5%; Infusion (parenteral); 50 ml
• Dextrose; 50%; Infusion (parenteral); 500 ml
• Diazepam; 10mg/2ml; injection; 2 ml
• Diazepam; 5mg; Tablet; 100 Tablets
• Diazepam; 5mg; Tablet; 14 Tablets
• Diazoxide; 20mg; Capsule; 100 Capsules
• Digoxin; 250mcg; Tablet; 30 Tablets
• Digoxin; 62.5mcg; Tablet; 100 Tablets
• Dinoprostone; 0.5mg; Tablet; 10 Tablets
• Dinoprostone; 1mg/3g; Syringe, Prefilled; 3 g
• Dobutamine; 250mg/20ml; injection; 20 ml
• Docetaxel; 20mg/ml; injection; 1 ml
• Docetaxel; 80mg/4ml; injection; 4 ml
• Dolutegravir; 50mg; tablet, scored; 30 Tablets
• Dopamine; 200mg/5ml; injection; 5 ml
• Doxorubicin; 10mg/5ml; injection; 5 ml
• Doxorubicin; 50mg/25ml; injection; 25 ml
• Doxycycline; 100mg; Tablet; 100 Tablets
• Efavirenz; 50mg; Capsule; 28 Capsules
• Electrolyte No 2 Solution: Na, K, Cl, Mg, Hpo4, Dextrose; injection; 1 L
• Emulsifying; BP; Ointment; 500 g
• Enoxaparin; 40mg/0.4ml; Syringe, Prefilled; 0.4 ml
• Enoxaparin; 60mg/0.6ml; Syringe, Prefilled; 0.6 ml
• Enoxaparin; 80mg/0.8ml; Syringe, Prefilled; 0.8 ml
• Epinephrine (Adrenaline); 0.15mg/0.3ml; auto-pen; 0.3 ml
• Epinephrine (Adrenaline); 0.3mg/0.3ml; auto-pen; 0.3 ml
• Epirubicin; 10mg/5ml; injection; 5 ml
• Epirubicin; 50mg/25ml; injection; 25 ml
• Ergometrine, Oxytocin; 500mcg, 5IU; injection; 1 ml
• Ertapenem; 1g; injection; 1 Injection
• Erythropoietin; 10000IU; injection; 1 ml
• Erythropoietin; 2000IU/0.3ml; Syringe, Prefilled; 1 Syringe, Pre-filled
• Erythropoietin; 30000IU/0.6ml; Syringe, Prefilled; 1 Syringe, Pre-filled
• Erythropoietin; 4000IU; injection; 1 ml
• Erythropoietin; 6000IU; injection; 1 ml
• Estradiol, Norethisterone Acetate; 1mg, 0.5mg; Tablet; 28 Tablets
• Estradiol, Norethisterone Acetate; 2mg, 1mg; Tablet; 28 Tablets
• Estradiol; 1mg; Tablet; 28 Tablets
• Estradiol; 2mg; Tablet; 28 Tablets
• Estrogen, Conjugated ; 0.3mg; Tablet; 28 Tablets
• Ethambutol; 400mg; Tablet; 100 Tablets
• Ethambutol; 400mg; Tablet; 56 Tablets
• Ethambutol; 400mg; Tablet; 84 Tablets
• Ethionamide; 250mg; Tablet; 250 Tablets
• Ethionamide; 250mg; Tablet; 28 Tablets
• Ethionamide; 250mg; Tablet; 56 Tablets
• Ethionamide; 250mg; Tablet; 84 Tablets
• Etomidate; 20mg/10ml; injection; 10 ml
• Etonogestrel; 68mg; Implant; 1 Device
• Etoposide; 100mg; injection (Section 21); 1 Injection
• Exemestane; 25mg; Tablet; 28 Tablets
• Fenoterol; 1.25mg/2ml; solution, inhalation; 60 UDVs (2ml)
• Fentanyl; 500mcg/10ml; injection; 10 ml
• Ferrous Gluconate; 350mg/5ml; Syrup; 100 ml
• Ferrous Sulfate Co; 170mg; Tablet; 100 Tablets
• Ferrous Sulfate Co; 170mg; Tablet; 56 Tablets
• Ferrous Sulfate Co; 170mg; Tablet; 84 Tablets
• Filgrastim; 30MU; Syringe, Prefilled; 1 Syringe, Pre-filled
• Filgrastim; 48MU; Syringe, Prefilled; 1 Syringe, Pre-filled
• Flucloxacillin; 250mg; Capsule; 100 Capsules
• Fluconazole; 200mg/100ml; Infusion (parenteral); 100 ml
• Fluconazole; 200mg; Tablet; 28 Tablets
• Fluconazole; 50mg/5ml; Suspension; 35 ml
• Fluconazole; 50mg; Tablet; 14 Tablets
• Fludarabine; 10mg; Tablet; 20 Tablets
• Fludarabine; 50mg; injection; 1 Injection
• Fluocinolone Acetonide; 0.025%; Ointment; 15 g
• Fluorouracil; 5%; Ointment; 20 g
• Fluoxetine; 20mg; Capsule; 100 Capsules
• Flupentixol; 20mg/ml; injection; 1 ml
• Fluticasone Propionate; 50mcg; Spray, Nasal; 120 Doses
• Folic Acid; 5mg; Tablet; 100 Tablets
• Formoterol; 12mcg; Inhaler; 120 Doses
• Fosfomycin; Granules; 1 Sachet (3g)
• Furosemide; 10mg/ml; Solution; 100 ml
• Furosemide; 20mg/2ml; injection; 2 ml
• Furosemide; 250mg/25ml; injection; 25 ml
• Furosemide; 40mg; Tablet; 112 Tablets
• Furosemide; 40mg; Tablet; 250 Tablets
• Furosemide; 500mg; Tablet; 100 Tablets
• Furosemide; 50mg/5ml; injection; 5 ml
• Ganciclovir; 500mg; injection; 1 Injection
• Gemcitabine; 1g; injection; 1 Injection
• Gemcitabine; 200mg; injection; 1 Injection
• Gentamicin; 20mg/2ml; injection; 2 ml
• Gentamicin; 80mg/2ml; injection; 2 ml
• Glibenclamide; 5mg; Tablet; 100 Tablets
• Glibenclamide; 5mg; Tablet; 84 Tablets
• Glucagon; 1mg; injection; 1 ml
• Glucometer; Medical device; 1 Device
• Glycerol; BP; Liquid; 500 ml
• Glycerol; 0.891ml; Suppository; 12 Suppositories
• Glycerol; 1.698ml; Suppository; 12 Suppositories
• Glyco Thymol Co; Mouthwash; 100 ml
• Glycopyrronium Bromide; 400mcg/2ml; injection; 2 ml
• Glycopyrronium Bromide; 50mcg; Inhaler; 30 Doses
• Goserelin; 10.8mg; Syringe, Prefilled; 1 Syringe, Pre-filled
• Goserelin; 3.6mg; Syringe, Prefilled; 1 Syringe, Pre-filled
• Granisetron; 1mg; injection; 1 Injection
• Granisetron; 3mg/3ml; injection; 3 ml
• Half Darrow With Glucose; 5%; Infusion (parenteral); 200 ml
• Half Darrow With Glucose; 5%; Infusion (parenteral); 500 ml
• Haloperidol; 1.5mg; Tablet; 100 Tablets
• Haloperidol; 5mg; Tablet; 100 Tablets
• Haloperidol; 5mg; Tablet; 28 Tablets
• Haloperidol; 5mg; Tablet; 56 Tablets
• Halothane; Liquid; 250 ml
• Heparin; 25000IU/5ml; injection; 5 ml
• Heparin; 5000IU/5ml; injection; 5 ml
• HUMAN COAGULATION CONCENTRATE COMPLEX: FACTOR VIII COMPLEX 1 000 IU INJECTION, UNIT CONTAINING - A HIGH SPECIFIC FACTOR VIII (FACTOR VIII: C) ACTIVITY - VON WILLEBRAND FACTOR (FACTOR
• HUMAN COAGULATION CONCENTRATE COMPLEX: FACTOR VIII COMPLEX 500 IU INJECTION, UNIT CONTAINING - A HIGH SPECIFIC FACTOR VIII (FACTOR VIII: C) ACTIVITY - VON WILLEBRAND FACTOR (FACTOR
• Human Coagulation Factor Concentrate: Activated Prothrombin Complex; 500IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Activated Prothrombin Complex; 1,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Ix Complex; 500IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viia Complex; 100,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viia Complex; 250,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viia Complex; 50,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viii Complex; 1,000IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viii Complex; 300IU; injection; 1 Injection
• Human Coagulation Factor Concentrate: Factor Viii Complex; 500IU; injection; 1 Injection
• Hyaluronic Acid; 10mg/ml; Syringe, Prefilled; 0.4 ml
• Hyaluronic Acid; 10mg/ml; Syringe, Prefilled; 0.55 ml
• Hydralazine; 25mg; Tablet; 56 Tablets
• Hydralazine; 25mg; Tablet; 84 Tablets
• Hydrochlorothiazide; 12.5mg; Tablet; 28 Tablets
• Hydrocortisone; 1%; Cream; 20 g
• Hydrocortisone; 1%; Ointment; 25 g
• Hydrocortisone; 10mg; Tablet; 100 Tablets
• Hydroxypropylmethylcellulose; 3mg/ml; Drop, Eye; 20 ml
• Hydroxyurea; 500mg; Capsule; 100 Capsules
• Hyoscine butylbromide; 10mg; Tablet; 10 Tablets
• Hyoscine butylbromide; 20mg/ml; injection; 1 ml
• Hyoscine butylbromide; 5mg/5ml; Syrup; 100 ml
• Ibandronic acid; 6mg; injection; 6 ml
• Ibuprofen; 100mg/5ml; Suspension; 100 ml
• Ibuprofen; 400mg; Tablet; 100 Tablets
• Ibuprofen; 400mg; Tablet; 84 Tablets
• Ifosfamide; 1g; injection; 1 Injection
• Ifosfamide; 2g; injection; 1 Injection
• Ifosfamide; 500mg; injection; 1 Injection
• Imatinib; 100mg; Capsule; 60 Capsules
• Imatinib; 400mg; Capsule; 30 Capsules
• Imipenem, Cilastatin; 500mg, 500mg; injection; 1 Injection
• Immunoglobulin, Anti-D; 100mcg; injection; 2 ml
• Immunoglobulin, Hepatitis B; 100IU/2ml; injection; 1 Injection
• Immunoglobulin, Human, Normal; 12g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Human, Normal; 16%; injection; 2 ml
• Immunoglobulin, Human, Normal; 16%; injection; 5 ml
• Immunoglobulin, Human, Normal; 1g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Human, Normal; 3g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Human, Normal; 6g; Infusion (parenteral); 1 Injection
• Immunoglobulin, Rabies; 150IU/ml; injection; 2 ml
• Indometacin; 25mg; Capsule; 100 Capsules
• Insulin, Biosynthetic, Human, Isophane; 100IU/ml; injection; 10 ml
• Insulin, Biosynthetic, Human, Isophane; 100IU/ml; pen, prefilled; 3 ml
• Insulin, Biosynthetic, Human, Biphasic 30/70; 100IU/ml; injection; 10 ml
• Insulin, Biosynthetic, Human, Biphasic 30/70; 100IU/ml; pen, prefilled; 3 ml
• Insulin, Biosynthetic, Human, Soluble; 100IU/ml; injection; 10 ml
• Insulin, Biosynthetic, Human, Soluble; 100IU/ml; pen, prefilled; 3 ml
• Interferon Beta-1a; 6MIU; injection; 1 Injection
• Interferon Beta-1b; 8MIU; injection; 1 Injection
• Iohexol; 300mg/ml; injection; 100 ml
• Iohexol; 300mg/ml; injection; 20 ml
• Iohexol; 300mg/ml; injection; 50 ml
• Iohexol; 350mg/ml; injection; 100 ml
• Iohexol; 350mg/ml; injection; 50 ml
• Iomeprol; 400mg/ml; injection; 100 ml
• Iopamidol; 370mg/ml; injection; 100 ml
• Iopamidol; 370mg/ml; injection; 50 ml
• Iopromide; 300mg/ml; injection; 50 ml
• Iopromide; 370mg/ml; injection; 100 ml
• Ipratropium Bromide; 20mcg; Inhaler; 200 Doses
• Ipratropium Bromide; 250mcg/2ml; solution, inhalation; 60 UDVs (2ml)
• Ipratropium Bromide; 500mcg/2ml; solution, inhalation; 60 UDVs (2ml)
• Irinotecan; 100mg/5ml; injection; 5 ml
• Irinotecan; 40mg/2ml; injection; 2 ml
• Iron (III) Hydroxide Dextran Complex; 100mg/2ml; injection; 2 ml
• Iron (III) Hydroxide Dextran Complex; 500mg/10ml; injection; 10 ml
• Iron Sucrose Co; 100mg/5ml; injection; 5 ml
• Isoflurane; Liquid; 250 ml
• Isosorbide Dinitrate; 10mg; Tablet; 84 Tablets
• Isosorbide Dinitrate; 5mg; Tablet; 50 Tablets
• Isosorbide mononitrate; 20mg; Tablet; 56 Tablets
• IUD, Copper; Implant; 1 Device
• IUD, Levonorgestrel; 52mg; Implant; 1 Device
• Ketamine; 1000mg/10ml; injection; 10 ml
• Ketamine; 200mg/20ml; injection; 20 ml
• Ketamine; 500mg/10ml; injection; 10 ml
• Ketoconazole; 200mg; Tablet; 30 Tablets
• Lactulose; 3.35g/5ml; Syrup; 150 ml
• Lactulose; 3.35g/5ml; Syrup; 500 ml
• Lamotrigine; 100mg; Tablet; 56 Tablets
• Lamotrigine; 200mg; Tablet; 56 Tablets
• Lamotrigine; 25mg; Tablet; 56 Tablets
• Lamotrigine; 50mg; Tablet; 56 Tablets
• Lanolin; 3%; ointment, eye; 3.5 g
• Leflunomide; 10mg; Tablet; 30 Tablets
• Leflunomide; 20mg; Tablet; 30 Tablets
• Letrozole; 2.5mg; Tablet; 28 Tablets
• Levodopa, Carbidopa; 100mg, 25mg; Tablet; 100 Tablets
• Levodopa, Carbidopa; 250mg, 25mg; Tablet; 100 Tablets
• Levofloxacin; 250mg; Tablet; 28 Tablets
• Levofloxacin; 500mg; Tablet; 28 Tablets
• Levonorgestrel, Ethinylestradiol, Triphasic; Tablet; 28 Tablets
• Levonorgestrel, Ethinylestradiol; 0.15mg, 0.03mg; Tablet (Monophasic); 28 Tablets
• Levonorgestrel; 0.03mg; Tablet; 28 Tablets
• Levonorgestrel; 1.5mg; Tablet; 1 Tablet
• Levothyroxine Sodium; 100mcg; Tablet; 30 Tablets
• Levothyroxine Sodium; 25mcg; Tablet; 28 Tablets
• Levothyroxine Sodium; 50mcg; Tablet; 100 Tablets
• Levothyroxine Sodium; 50mcg; Tablet; 30 Tablets
• Lidocaine, Epinephrine (Adrenaline); 2%, 12.5mg; dental cartridge; 1.8 ml
• Lidocaine; 1%; injection (not for iv use); 20 ml
• Lidocaine; 10%; injection; 5 ml
• Lidocaine; 2%; dental cartridge; 1.8 ml
• Lidocaine; 2%; injection (not for iv use); 20 ml
• Lidocaine; 2%; injection (not for iv use); 5 ml
• Linezolid; 100mg/5ml; Suspension; 150 ml
• Linezolid; 600mg/300ml; Infusion (parenteral); 300 ml
• Linezolid; 600mg; Tablet; 10 Tablets
• Liquid Paraffin; BP; Liquid; 200 ml
• Lopinavir, Ritonavir; 100mg, 25mg; Tablet; 60 Tablets
• Lopinavir, Ritonavir; 40mg, 10mg; Capsule; 120 Capsules
• Lopinavir, Ritonavir; 80mg/ml, 20mg/ml; Solution; 60 ml
• Lorazepam; 1mg; Tablet; 100 Tablets
• Lorazepam; 2.5mg; Tablet; 100 Tablets
• Losartan; 100mg; Tablet; 28 Tablets
• Losartan; 50mg; Tablet; 30 Tablets
• Lubricant, Jelly; Gel; 1 sachet (2.5g)
• Lubricant, Jelly; Gel; 50 g
• Lyophilised Plasma; Infusion (parenteral); 200 ml
• Lyophilised Plasma; Infusion (parenteral); 50 ml
• Magnesium Sulfate; 50%; injection; 2 ml
• Mannitol; 25%; injection; 50 ml
• Mannitol; 5%; Infusion (parenteral); 3 L
• Mebendazole; 100mg/5ml; Suspension; 30 ml
• Mebendazole; 100mg; Tablet; 6 Tablets
• Mebendazole; 500mg; Tablet; 1 Tablet
• Medroxyprogesterone; 10mg; Tablet; 30 Tablets
• Medroxyprogesterone; 150mg; injection; 1 Injection
• Medroxyprogesterone; 5mg; Tablet; 30 Tablets
• Melphalan; 2mg; Tablet; 25 Tablets
• Melphalan; 50mg; injection; 1 Injection
• Mercaptopurine; 50mg; Tablet; 25 Tablets
• Meropenem; 1g; injection; 30 ml
• Meropenem; 500mg; injection; 20 ml
• Mesalazine; 400mg; Tablet; 90 Tablets
• Mesna; 400mg; injection; 1 Injection
• Metformin; 500mg; Tablet; 112 Tablets
• Methadone; 2mg; Solution; 60 ml
• Methotrexate; 1g/10ml; injection; 10 ml
• Methotrexate; 2.5mg; Tablet; 100 Tablets
• Methotrexate; 50mg/2ml; injection; 2 ml
• Methotrexate; 5g/50ml; injection; 50 ml
• Methyl Salicylate; 10%; Ointment; 25 g
• Methyl Salicylate; 10%; Ointment; 25 g
• Methyldopa; 250mg; Tablet; 56 Tablets
• Methyldopa; 250mg; Tablet; 84 Tablets
• Methylphenidate; 10mg; Tablet; 30 Tablets
• Methylprednisolone Acetate; 40mg/ml; injection; 2 ml
• Methylprednisolone Acetate; 40mg/ml; injection; 5 ml
• Methylprednisolone Sodium Succinate; 500mg/8ml; injection; 8 ml
• Methylprednisolone; 40mg; injection; 1 Injection
• Metoclopramide; 10mg/2ml; injection; 2 ml
• Metoclopramide; 10mg; Tablet; 100 Tablets
• Metoclopramide; 5mg/5ml; Syrup; 100 ml
• Metronidazole; 200mg/5ml; Suspension; 100 ml
• Metronidazole; 200mg; Tablet; 21 Tablets
• Metronidazole; 200mg; Tablet; 21 Tablets
• Metronidazole; 200mg; Tablet; 250 Tablets
• Metronidazole; 200mg; Tablet; 28 Tablets
• Metronidazole; 400mg; Tablet; 100 Tablets
• Metronidazole; 400mg; Tablet; 21 Tablets
• Micafungin; 100mg; injection; 1 Injection
• Micafungin; 50mg; injection; 1 Injection
• Miconazole; 2%; Gel, Oral; 30 g
• Midazolam; 15mg; Tablet; 20 Tablets
• Midazolam; 50mg/10ml; injection; 10 ml
• Midazolam; 7.5mg; Tablet; 20 Tablets
• Mifepristone; 200mg; Tablet; 3 Tablets
• Minoxidil; 10mg; Tablet; 100 Tablets
• Minoxidil; 5mg; Tablet; 100 Tablets
• Misoprostol; 200mcg; Tablet; 60 Tablets
• Montelukast; 10mg; Tablet; 30 Tablets
• Montelukast; 4mg; Tablet, chew; 30 Tablets
• Montelukast; 5mg; Tablet; 30 Tablets
• Morphine; BP; Powder; 10 g
• Morphine; 10mg; Tablet, MR; 60 Tablets
• Morphine; 30mg; Tablet, MR; 60 Tablets
• Morphine; 60mg; Tablet, MR; 60 Tablets
• Moxifloxacin; 400mg/250ml; injection; 250 ml
• Moxifloxacin; 400mg; Tablet; 10 Tablets
• Moxifloxacin; 400mg; Tablet; 28 Tablets
• Moxifloxacin; 400mg; Tablet; 5 Tablets
• Multichamber TPN for Adults: High volume bag with electrolytes, Very high protein, Very high calorie for central line; Infusion (parenteral); 2 L
• Multichamber TPN for Adults: High volume bag with electrolytes: high protein, very high calorie for central line; Infusion (parenteral); 2 L
• Multichamber TPN for Adults: High volume bag with electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 2 L
• Multichamber TPN for Adults: Low volume bag with electrolytes: low protein, moderate calorie through central line; Infusion (parenteral); 1.5 L
• Multichamber TPN for Adults: Moderate volume bag with electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 1.5 L
• Multichamber TPN for Adults: Moderate volume bag without electrolytes: Moderate protein, high calorie through central line; Infusion (parenteral); 1 L
• Multichamber TPN for Adults: Very low volume weaning bag with electrolytes: very low protein, low calorie for central line; Infusion (parenteral); 1 L
• Mycophenolate Mofetil; 200mg/ml; Suspension; 175 ml
• Mycophenolate Mofetil; 250mg; Capsule; 100 Capsules
• Mycophenolate Mofetil; 500mg; Tablet; 50 Tablets
• Mycophenolic Acid; 180mg; Tablet; 120 Tablets
• Mycophenolic Acid; 360mg; Tablet; 120 Tablets
• Naloxone; 400mcg/ml; injection; 1 ml
• Naloxone; 40mcg/2ml; injection; 2 ml
• Neonatal Maintenance, Dextrose (Potassium Free); 33,5,33,100mmol; Infusion (parenteral); 200 ml
• Neonatal Maintenance, Dextrose; 20,15,2.5,0.5,21,2mmol, 10%; Infusion (parenteral); 200 ml
• Neostigmine; 2.5mg/ml; injection; 1 ml
• Nevirapine; 200mg; Tablet; 56 Tablets
• Nevirapine; 50mg/5ml; Suspension; 100 ml
• Nevirapine; 50mg/5ml; Suspension; 240 ml
• Nifedipine; 10mg; Capsule; 100 Capsules
• Nifedipine; 5mg; Capsule; 100 Capsules
• Nilotinib; 150mg; Capsule; 112 Capsules
• Nilotinib; 200mg; Capsule; 112 Capsules
• Nitrofurantoin; 100mg; Capsule; 50 Capsules
• Norethisterone Acetate; 5mg; Tablet; 30 Tablets
• Norethisterone Enanthate; 200mg/ml; injection; 1 ml
• Norgestrel, Ethinylestradiol; 0.5mg, 0.05mg; Tablet; 28 Tablets
• Nystatin; 100000IU/ml; Drop, Oral; 20 ml
• Octreotide; 0.05mg/ml; injection; 1 Injection
• Octreotide; 0.1mg/ml; injection; 1 Injection
• Olanzapine; 10mg; Tablet; 28 Tablets
• Olanzapine; 2.5mg; Tablet; 28 Tablets
• Olanzapine; 5mg; Tablet; 28 Tablets
• Olopatadine; 1mg/ml; Drop, Eye; 5 ml
• Ondansetron; 4mg/2ml; injection; 2 ml
• Ondansetron; 4mg; Tablet, dispersible; 10 Tablets
• Ondansetron; 8mg/4ml; injection; 4 ml
• Ondansetron; 8mg; Tablet; 10 Tablets
• Oral Rehydration; Powder; 1 Sachet
• Orphenadrine; 50mg; Tablet; 28 Tablets
• Orphenadrine; 50mg; Tablet; 56 Tablets
• Orphenadrine; 50mg; Tablet; 84 Tablets
• Oxaliplatin; 100mg; injection; 1 Injection
• Oxaliplatin; 50mg; injection; 1 Injection
• Oxazepam; 10mg; Tablet; 100 Tablets
• Oxazepam; 30mg; Tablet; 100 Tablets
• Oxybuprocaine; 0.4%; Drop, Eye; 3 ml
• Oxybutynin; 5mg; Tablet; 84 Tablets
• Oxymetazoline; 0.025%; Drop, Eye; 15 ml
• Oxymetazoline; 0.025%; Drop, Nasal; 10 ml
• Oxymetazoline; 0.05%; Drop, Nasal; 10 ml
• Oxymetazoline; 0.05%; Spray, Nasal; 15 ml
• Oxytocin; 5IU/ml; injection; 1 ml
• Paclitaxel; 100mg/16.7ml; injection; 16.7 ml
• Paclitaxel; 30mg/5ml; injection; 5 ml
• Pancreatin: Lipase, Amylase, Protease; 150mg; Capsule; 100 Capsules
• Pancreatin: Lipase, Amylase, Protease; 300mg; Capsule; 100 Capsules
• Pantoprazole; 40mg; injection; 1 Injection
• Paracetamol; 120mg/5ml; Syrup; 100 ml
• Paracetamol; 120mg/5ml; Syrup; 50 ml
• Paracetamol; 120mg/5ml; Syrup; 500 ml
• Pethidine; 25mg/ml; injection; 1 ml
• Phenobarbital, Vitamin B3 (Nicotinamide), Vitamin B6 (Pyridoxine), Vitamin B2 (Riboflavin), Vitamin B1 (Thiamine); 16mg/5ml, 10mg/5ml, 0.25mg/5ml, 1mg/5ml, 3mg/5ml; Syrup; 100 ml
• Phenobarbital; 30mg; Tablet; 28 Tablets
• Phenobarbital; 30mg; Tablet; 56 Tablets
• Phenobarbital; 30mg; Tablet; 84 Tablets
• Phenoxymethylpenicillin; 125mg/5ml; Suspension; 100 ml
• Phenoxymethylpenicillin; 250mg/5ml; Suspension; 100 ml
• Phenoxymethylpenicillin; 250mg; Tablet; 100 Tablets
• Phenoxymethylpenicillin; 250mg; Tablet; 40 Tablets
• Phenylephrine; 10mg/ml; injection; 1 ml
• Phenytoin; 100mg; Capsule; 100 Capsules
• Phenytoin; 100mg; Capsule; 84 Capsules
• Phenytoin; 250mg/5ml; injection; 5 ml
• Phospholipids, Total; 100mg/4ml; injection; 4 ml
• Phospholipids, Total; 200mg/8ml; injection; 8 ml
• Pilocarpine; 1%; Drop, Eye; 15 ml
• Piperacillin, Tazobactam; 4g, 500mg; injection; 30 ml
• Polystyrene Sulfonate; Powder; 454 g
• Potassium Chloride; BP; Powder; 500 g
• Potassium Chloride; 15%; injection; 10 ml
• Potassium Chloride; 600mg; Tablet; 100 Tablets
• Potassium Citrate; BP; Suspension; 200 ml
• Povidone Iodine; 1%; Liquid; 100 ml
• Povidone Iodine; 10%; Liquid; 1 L
• Povidone Iodine; 10%; Ointment; 25 g
• Povidone Iodine; 10%; Ointment; 500 g
• Povidone Iodine; 5%; Cream; 25 g
• Povidone Iodine; 5%; Cream; 500 g
• Pramipexole; 0.125mg; Tablet; 100 Tablets
• Pramipexole; 0.25mg; Tablet; 100 Tablets
• Pramipexole; 1mg; Tablet; 100 Tablets
• Praziquantel; 500mg; Tablet; 100 Tablets
• Prednisolone; 1%; Drop, Eye; 5 ml
• Prednisone; 5mg; Tablet; 100 Tablets
• Prednisone; 5mg; Tablet; 40 Tablets
• Prednisone; 5mg; Tablet; 56 Tablets
• Promethazine; 25mg/ml; injection; 1 ml
• Promethazine; 25mg; Tablet; 100 Tablets
• Promethazine; 50mg/2ml; injection; 2 ml
• Promethazine; 5mg/5ml; Elixir; 100 ml
• Propofol; 10mg/ml; injection; 20 ml
• Propofol; 10mg/ml; injection; 50 ml
• Propranolol; 10mg; Tablet; 250 Tablets
• Propranolol; 10mg; Tablet; 28 Tablets
• Propranolol; 10mg; Tablet; 50 Tablets
• Propranolol; 10mg; Tablet; 84 Tablets
• Propranolol; 40mg; Tablet; 250 Tablets
• Propranolol; 40mg; Tablet; 56 Tablets
• Propranolol; 40mg; Tablet; 84 Tablets
• Propylene Glycol; BP; Liquid; 2.5 L
• Pyrazinamide; 500mg; Tablet; 28 Tablets
• Pyrazinamide; 500mg; Tablet; 56 Tablets
• Pyrazinamide; 500mg; Tablet; 84 Tablets
• Pyridostigmine; 10mg; Tablet; 50 Tablets
• Pyridostigmine; 60mg; Tablet; 150 Tablets
• Quetiapine; 100mg; Tablet; 90 Tablets
• Quetiapine; 200mg; Tablet; 60 Tablets
• Quetiapine; 25mg; Tablet; 100 Tablets
• Quetiapine; 300mg; Tablet; 60 Tablets
• Quinine; 300mg/ml; injection; 1 ml
• Raltegravir; 100mg; Tablet; 56 Tablets
• Raltegravir; 25mg; Tablet; 56 Tablets
• Raltegravir; 400mg; Tablet; 56 Tablets
• Ranitidine; 50mg/2ml; injection; 2 ml
• Recombinant Anthihaemophilic Factor VIII; 1000IU; injection; 1 Dose
• Recombinant Anthihaemophilic Factor VIII; 250IU; injection; 1 Dose
• Recombinant Anthihaemophilic Factor VIII; 500IU; injection; 1 Dose
• Rifampicin, Isoniazid; 60mg, 60mg; Tablet; 28 Tablets
• Rifampicin, Isoniazid; 60mg, 60mg; Tablet; 56 Tablets
• Rifampicin, Isoniazid; 75mg, 50mg; Tablet; 84 Tablets
• Rifampicin, Pyrazinamide, Ethambutol, Isoniazid; 150mg, 400mg, 275mg, 75mg; Tablet; 28 Tablets
• Rifampicin, Pyrazinamide, Isoniazid; 75mg, 150mg, 50mg; Tablet; 84 Tablets
• Rifampicin; 150mg; Capsule; 100 Capsules
• Rifapentine; 150mg; Tablet; 24 Tablets
• Ringer Lactate; Infusion (parenteral); 1 L
• Ringer Lactate; Infusion (parenteral); 200 ml
• Risedronic Acid; 35mg; Tablet; 4 Tablets
• Risperidone; 0.5mg; Tablet; 30 Tablets
• Risperidone; 1mg/ml; Solution; 30 ml
• Risperidone; 1mg; Tablet; 30 Tablets
• Risperidone; 2mg; Tablet; 30 Tablets
• Risperidone; 3mg; Tablet; 30 Tablets
• Ritonavir; 100mg; Suspension; 30 Sachets
• Ritonavir; 100mg; Tablet; 56 Tablets
• Rituximab; 100mg/10ml; injection; 10 ml
• Rituximab; 500mg/50ml; injection; 50 ml
• Rocuronium Bromide; 50mg/5ml; injection; 5 ml
• Rosuvastatin; 10mg; Tablet; 30 Tablets
• Salbutamol, Ipratropium Bromide; 2.5mg/2.5ml, 0.5mg/2.5ml; solution, inhalation; 60 UDVs (2.5ml)
• Salmeterol, Fluticasone; 25mcg, 250mcg; Inhaler; 120 Doses
• Salmeterol, Fluticasone; 25mcg, 50mcg; Inhaler; 120 Doses
• Selenium Sulfide; 2.5%; Suspension; 50 ml
• Senna Glycosides; 13.5mg; Tablet; 20 Tablets
• Sevoflurane; BP; Liquid; 250 ml
• Silver Sulfadiazine; 1%; Cream; 250 g
• Silver Sulfadiazine; 1%; Cream; 50 g
• Silver Sulfadiazine; 1%; Cream; 500 g
• Sirolimus; 1mg; Tablet; 30 Tablets
• Sodium Bicarbonate; 4%; injection; 50 ml
• Sodium Bicarbonate; 4.2%; Infusion (parenteral); 200 ml
• Sodium Bicarbonate; 8.5%; injection; 50 ml
• Sodium Chloride, Dextrose; 0.2%, 5%; Infusion (parenteral); 200 ml
• Sodium Chloride, Dextrose; 0.45%, 5%; Infusion (parenteral); 1 L
• Sodium Chloride, Dextrose; 0.9%, 5%; Infusion (parenteral); 1 L
• Sodium Chloride, Dextrose; 0.9%, 5%; Infusion (parenteral); 200 ml
• Sodium Chloride; BP; Powder; 500 g
• Sodium Chloride; 0.45%; Infusion (parenteral); 1 L
• Sodium Chloride; 0.9%; Infusion (parenteral); 1 L
• Sodium Chloride; 0.9%; Infusion (parenteral); 100 ml
• Sodium Chloride; 0.9%; Infusion (parenteral); 200 ml
• Sodium Chloride; 0.9%; Infusion (parenteral); 200 ml
• Sodium Chloride; 0.9%; Infusion (parenteral); 50 ml
• Sodium Chloride; 0.9%; solution, irrigation, bag; 1 L
• Sodium Chloride; 0.9%; solution, irrigation, bag; 3 L
• Sodium Chloride; 0.9%; solution, irrigation, bottle; 1 L
• Sodium Chloride; 0.9%; solution, irrigation; 30 ml
• Sodium Chloride; 5%; Infusion (parenteral); 200 ml
• Sodium Phosphate, Sodium Acid Phosphate; Enema; 135 ml
• Sodium, Potassium, Calcium, Lactate; 131mmol, 5mmol, 108mmol, 29mmol; Infusion (parenteral) (Plasmalyte L); 1 L
• Sodium, Potassium, Calcium, Lactate; 35mmol/L, 12mmol/L, 47mmol/L, 50g/L; Infusion (parenteral) (Paediatric Maintenance); 500 ml
• Sodium, Potassium, Calcium, Lactate; 35mmol/L, 12mmol/L, 47mmol/L, 50g/L; Infusion (parenteral) (Paediatric Maintenance); 200 ml
• Soft Paraffin, White; BP; Ointment; 500 g
• Somatropin; 10mg/1.5ml; cartridge; 1.5 ml
• Somatropin; 5mg/1.5ml; cartridge; 1.5 ml
• Sorbitol; 70%; Solution; 500 ml
• Spacer With Mask For Adults; Medical device; 1 Device
• Spacer With Mask For Children; Medical device; 1 Device
• Spacer With Mask For Infants; Medical device; 1 Device
• Spironolactone; 100mg; Tablet; 60 Tablets
• Spironolactone; 25mg; Tablet; 200 Tablets
• Spironolactone; 25mg; Tablet; 56 Tablets
• Spironolactone; 25mg; Tablet; 84 Tablets
• Streptokinase; 1.5MIU; injection; 1 Injection
• Sulfamethoxazole, Trimethoprim; 400mg, 80mg; Tablet (Co-trimoxazole); 100 Tablets
• Sulfamethoxazole, Trimethoprim; 400mg/5ml, 80mg/5ml; injection; 5 ml
• Sulfasalazine; 500mg; Tablet; 100 Tablets
• Sunscreen; 30SPF; Cream; 150 ml
• Suxamethonium; 100mg/2ml; injection; 2 ml
• Syrup, Simplex; BP; Syrup; 2.5 L
• Tacrolimus; 0.5mg; Capsule; 30 Capsules
• Tacrolimus; 1mg; Capsule; 30 Capsules
• Tacrolimus; 5mg; Capsule; 30 Capsules
• Tamoxifen; 20mg; Tablet; 28 Tablets
• Tenofovir; 300mg; Tablet; 28 Tablets
• Teriflunomide; 14mg; Tablet; 28 Tablets
• Terizidone; 250mg; Capsule; 100 Capsules
• Test: Blood Glucose; test strip; 50 Test Strips
• Test: TB LAM AG; test kit; 25 Test Strips
• Test: Urine, Gluc., Prot., Bl., pH, Ket., Leuc., Nit., Bilir., Urob.; test kit; 100 Test Strips
• Tetracaine, Arnica, Salvia, Aluminium; Ointment; 10 g
• Thalidomide; 50mg; Capsule; 28 Capsules
• Theophylline; 200mg; Tablet, MR; 60 Tablets
• Theophylline; 300mg; Tablet, MR; 60 Tablets
• Timolol, Bimatoprost; 5mg/ml, 0.3mg/ml; Drop, Eye; 3 ml
• Timolol, Brimonidine; 5mg/ml, 2mg/ml; Drop, Eye; 5 ml
• Timolol, Travoprost; 5mg/ml, 40mcg/ml; Drop, Eye; 2.5 ml
• Tioguanine; 40mg; Tablet; 25 Tablets
• Topiramate; 100mg; Tablet; 60 Tablets
• Topiramate; 15mg; Capsule, Sprinkle; 60 Capsules
• Topiramate; 25mg; Tablet; 60 Tablets
• Topiramate; 50mg; Tablet; 60 Tablets
• TPN for Adults: High volume bag with electrolytes: high protein, high calorie for central line; Infusion (parenteral); 2 L
• TPN for Adults: Moderate volume bag without electrolytes: Moderate protein, high calorie For IV infusion through central line. Multichamber bag containing: Amino Acids: a minimum of histidine,
• TPN for Adults: Very low volume weaning bag with electrolytes: very low protein, low calorie for peripheral line; Infusion (parenteral); 1 L
• Trace Elements; injection; 10 ml
• Tramadol; 100mg/2ml; injection; 2 ml
• Tramadol; 100mg; Tablet, MR; 60 Tablets
• Tranexamic Acid; 500mg/5ml; injection; 5 ml
• Tranexamic Acid; 500mg; Tablet; 30 Tablets
• Trastuzumab; 440mg; injection; 1 Injection
• Tretinoin; 0.025%; Gel; 20 g
• Tretinoin; 10mg; Capsule; 100 Capsules
• Tropicamide; 1%; Drop, Eye; 15 ml
• Vaccine: BCG; Injection; 20 Doses
• Vaccine: Diphtheria, Tetanus; 2IU/20IU; injection; 10 Doses
• Vaccine: Diptheria, Haemophilus Influenzae B, Pertussis, Polio, Tetanus, Hepatitis B; Syringe, Prefilled; 1 Dose
• Vaccine: Hepatitis B Adult; 20mcg/ml; injection; 1 Dose
• Vaccine: Hepatitis B Peadiatric; 10mcg/0.5ml; injection; 10 Doses
• Vaccine: Human Papillomavirus, Bivalent; injection; 2 Doses
• Vaccine: Influenza; Syringe, Prefilled; 1 Dose
• Vaccine: Measles; injection; 10 Doses
• Vaccine: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; injection; 1 Dose
• Vaccine: Pneumococcal, 23-Valent Polysaccharide; injection; 1 Dose
• Vaccine: Pneumococcal, Conjugated; Syringe, Prefilled; 1 Dose
• Vaccine: Rabies; injection; 1 Dose
• Vaccine: Rotavirus; Drop, Oral; 1 Dose
• Vaccine: Tetanus Toxoid; injection; 10 Doses
• Vaccine: Yellow Fever; injection; 1 Dose
• Valganciclovir; 450mg; Tablet; 60 Tablets
• Valproate Sodium; 100mg; Tablet, dispersible; 100 Tablets
• Valproic Acid, Valproate Sodium; 145mg, 333mg; Tablet, MR; 100 Tablets
• Valproic Acid, Valproate Sodium; 145mg, 333mg; Tablet, MR; 56 Tablets
• Valproic Acid, Valproate Sodium; 58mg, 133.2mg; Tablet, MR; 100 Tablets
• Valproic Acid, Valproate Sodium; 58mg, 133.2mg; Tablet, MR; 56 Tablets
• Valproic Acid, Valproate Sodium; 87mg, 199.8mg; Tablet, MR; 100 Tablets
• Valproic Acid, Valproate Sodium; 87mg, 199.8mg; Tablet, MR; 56 Tablets
• Valproic Acid; 200mg/5ml; Syrup; 300 ml
• Valproic Acid; 250mg/5ml; Syrup; 100 ml
• Vancomycin; 1g; injection; 1 Injection
• Vancomycin; 500mg; injection; 1 Injection
• Vecuronium; 4mg/2ml; injection; 2 ml
• Venlafaxine; 150mg; Tablet, MR; 30 Tablets
• Venlafaxine; 37.5mg; Tablet; 30 Tablets
• Venlafaxine; 75mg; Tablet; 30 Tablets
• Verapamil; 240mg; Tablet, MR; 30 Tablets
• Verapamil; 40mg; Tablet; 84 Tablets
• Vinblastine; 10mg/10ml; injection; 1 Injection
• Vincristine; 2mg/2ml; injection; 2 ml
• Vitamin A (Retinol); 100,000IU; Capsule; 50 Capsules
• Vitamin A (Retinol); 200,000IU; Capsule; 50 Capsules
• Vitamin A (Retinol); 50,000IU; Capsule; 50 Capsules
• Vitamin B1 (Thiamine); 100mg/ml; injection; 10 ml
• Vitamin B1 (Thiamine); 100mg; Tablet; 84 Tablets
• Vitamin B12 (Cyanocobalamin); 1mg/ml; injection; 1 ml
• Vitamin B3 (Nicotinamide); 100mg; Tablet; 28 Tablets
• Vitamin B3 (Nicotinamide); 100mg; Tablet; 84 Tablets
• Vitamin B6 (Pyridoxine); 25mg; Tablet; 100 Tablets
• Vitamin D (Alfacalcidol); 0.25mcg; Capsule; 30 Capsules
• Vitamin D (Alfacalcidol); 1mcg; Capsule; 30 Capsules
• Vitamin D2 (Ergocalciferol); 5,000IU/ml; Drop, Oral; 15 ml
• Vitamin D2 (Ergocalciferol); 50,000IU; Tablet; 100 Tablets
• Vitamin D3 (Calcitriol); 0.25mcg; Capsule; 30 Capsules
• Vitamin K1 (Phytomenadione); 10mg; injection; 1 ml
• Vitamin K1 (Phytomenadione); 2mg; injection; 0.2 ml
• Vitamin, Fat Soluble, Vitamin E; injection; 10 ml
• Vitamin, Multi; Drop, Oral; 25 ml
• Vitamin, Multi; injection; 10 ml
• Vitamin, Multi; Syrup; 100 ml
• Vitamin, Water Soluble; injection (for intravenous use in adults); 10 ml
• Warfarin; 5mg; Tablet; 100 Tablets
• Water For Injection; injection; 10 ml
• Water For Injection; injection; 20 ml
• Water For Irrigation; Liquid (Pour Water); 1 L
• Water For Irrigation; Liquid; 1 L
• Water For Irrigation; Liquid; 3 L
• Zidovudine, Lamivudine; 300mg, 150mg; Tablet; 56 Tablets
• Zidovudine, Lamivudine; 300mg, 150mg; Tablet; 56 Tablets
• Zidovudine; 100mg; Capsule; 100 Capsules
• Zidovudine; 300mg; Capsule; 56 Capsules
• Zidovudine; 50mg/5ml; Syrup; 200 ml
• Zinc Oxide, Castor Oil; Ointment; 25 g
• Zinc Sulfate; 10mg/5ml; Syrup; 150 ml
• Zinc Sulfate; 20mg; Tablet; 10 Tablets
• Zinc Sulfate; 20mg; Tablet; 100 Tablets
• Zuclopentixol Acetate; 50mg/ml; injection; 1 ml
• Zuclopentixol Decanoate; 200mg/ml; injection; 1 ml

END.

Reply:

1. The Interim Traditional Health Practitioners Council of South Africa (ITHPCSA/Council) has not been appointed. The appointment of the ITHPCSA was pending consultation between the Minister and the traditional health practitioners’ stakeholders. The consultation in this regard was held on 23-24 February 2023.

2. Regulation 6 of the Regulations relating to the appointment of members of the ITHPCSA provides that the Minister must publish the names of persons appointed to the Council in the Gazette. This regulation will be complied with upon finalization of the appointment of Members of the Council.

3. The Council once appointed will be expected to comply with the provisions of the Traditional Health Practitioners Act, 2007 (Act No. 22 of 2007).

4. The process to register traditional health practitioners will be undertaken subsequent to the appointment of the Council. Enquiries related to the registration and other matters can be directed to the Interim Registrar: Mr Kgereshi Mokwena as follows: (012) 3958018; (b) [email protected] (c) Dr AB Xuma Building, 1112 Voortrekker Rd, Pretoria Townlands 351-JR, Pretoria

END.

Reply:

1. Leave of absence in the Public Service is regulated in accordance with the Directive on Leave of Absence as published by the Department of Public Service and Administration in August 2021.

In accordance with the information as extracted from the PERSAL data set-

a) (i) The data as provided gives overall number of days counts that Nurses (in all categories as employed in the Public Health Sector) took in different leave categories during the financial years 2021/2022 and 2002/2023 is as per the table below:

The tables below provide a breakdown of the various categories of absenteeism per provinces.

NUMBER OF DAYS ABSENT BY NURSES (IN ALL CATEGORIES)
	EC	FS	GAU	KZN	LP	MPU	NW	NC	WC	Overall Total
Adoption (Workdays)	2	44	0	4	6	0	0	0	0	56
Discounting (Workdays)	102	1964	102	791	238	148	136	33	852	4366
Family Responsibility (Workdays)	7403	1542	2147	20103	14428	3755	2776	384	11203	63741
Gratuity (Workdays)	239	131	34	713	531	199	82	26	265	2220
Leave Without Pay (Calendar Days)	1540	269	359	3409	595	291	183	130	1421	8197
Maternity	576	163	217	1290	742	362	184	22	524	4080
Occupational Injuries/Diseases (Workdays)	185	41	67	833	1735	988	151	9	158	4167
Paternity (Workdays)	54	12	16	105	100	27	24	1	48	387
Permanent Incapacity Leave	7	1	121	13	598	3	155	9	7	914
Pre-Natal (Workdays)	308	161	154	1376	350	194	77	13	861	3494
Shop Steward/Office Bearer (Workdays)	663	183	87	1024	1052	258	183	78	595	4123
Sick-Full Pay (Workdays)	53276	19217	11953	145227	57858	17671	14473	2504	59599	381778
Special (Workdays)	1893	536	459	10173	3249	601	778	104	10795	28588
Temporary Incapacity Leave	1011	773	583	3358	872	431	343	37	1507	8915
Vacation - Full Pay (Workdays)	103013	37979	17654	214258	91977	38302	25891	4459	75251	608784

(ii) The Public Health Services does not make provision for a Job title of Operational Staff. It is requested that clear indication be provided on what is the meaning of Operational Staff.

(iii) The data as provided gives overall number of days counted that Clinicians (Medical Officers/ Specialist and Registrar’s) took in different leave categories during the financial years 2021/2022 and 2002/2023 is as per the table below.

The tables below provide a breakdown of the various categories of absenteeism per provinces.

NUMBER OF DAYS ABSENT BY CLINITIANS MEDICAL OFFICER / SPECIALIST / REGISTRARS
	EC	FS	GAU	KZN	LP	MPU	NW	NC	WC	Overall Total
Adoption (Workdays)	1	0	0	0	0	2	0	0	1	4
Discounting (Workdays)	14	49	35	206	157	36	69	5	317	888
Family Responsibility (Workdays)	265	174	146	1491	906	284	146	37	726	4175
Gratuity (Workdays)	17	1	0	19	19	10	2	0	16	84
Leave Without Pay (Calendar Days)	20	19	38	261	262	29	18	0	163	810
Maternity	58	40	51	239	161	78	46	3	158	834
Occupational Injuries/Diseases (Workdays)	13	2	16	99	173	107	12	0	11	433
Paternity (Workdays)	20	17	14	99	77	20	15	5	74	341
Permanent Incapacity Leave	0	0	0	0	0	0	0	0	1	1
Pre-Natal (Workdays)	51	15	27	407	118	28	15	1	112	774
Shop Steward/Office Bearer (Workdays)	3	0	2	17	37	15	0	0	118	192
Sick-Full Pay (Workdays)	2011	962	1293	17565	4604	1862	928	184	6852	36261
Special (Workdays)	572	801	263	3440	1328	409	226	33	4505	11577
Temporary Incapacity Leave	19	33	16	140	18	9	10	2	95	342
Vacation - Full Pay (Workdays)	7990	5993	4328	34780	13685	6903	4198	651	23370	101898

2. The National Department of Health is consulting with the Provincial Departments of Health to collate the full details in this regard.

END.

Reply:

(a)-(b) All health facilities have been affected by the load-shedding across the country and some core services, especially surgical interventions often have to be rescheduled. Fortunately, all hospitals have two back-up suppliers (e.g. generators and Uninterrupted Power Suppliers for theatres and ICU’s) and most of the Community Health Centres have one back-up supplier (e.g. generators). These back-up suppliers have assisted in reducing the impact of load-shedding and preventing untold harm to the patients. All health facilities are continuously adapting to ensure that they function optimally.

END.

Reply:

(1) My Department has appointed CSIR to conduct a due diligence exercise regarding the roll-out of solar energy to all health facilities across the country. (a) The proposed solar energy programme is going to cover the roll-out of the solar energy + battery storage as back-up supply to all the clinics, CHC’s, hospitals, EMS centres including the forensic laboratories. The objective of the exercise by CSIR is to identify the required critical consumption for critical areas of each health facility so that the department can be able:

- To compile a comprehensive business case that will assist the Department in justifying for the required budget;

- To identify critical areas within a “health facility” that requires a back-up service from the solar energy. CSIR is going to quantify the required size of solar energy for those critical areas;

- CSIR is going to consider different kits of inverters with batteries for the Clinics and CHC’s. Unlike solar panels, these kits are not easy to steal. They can be stored in a lockable room with burglar bars and with strict access control;

- To map out the roll-out implementation program for the required solar energy solution for each health facility;

- The study will also identify areas that can be funded by other donors like USAID including others that are interested to partner with the National Department of Health; and

- The exercise/study is expected to be completed at the end of April 2023.

(b) The expected start date of the roll-out of the solar energy programme is June 2023 depending on the availability of funding from the National State of Disaster Centre.

(c) The envisage completion date is going to be informed by the detailed analysis by CSIR.

(2) No.

END.

Reply:

In terms of the Constitution (Section 139 and its subsections) the prerogative to intervene in municipalities is bestowed upon the Provincial Government, having assessed the municipal deficiencies in fulfilling its Executive Obligations. Such an assessment ought to establish ‘clearly’, amongst others, political interference as a factor.

To the extent that two interventions were invoked in Emfuleni local municipality, with another recently terminated, a close-out report is being prepared by the Gauteng Provincial Executive Committee, which should indicate the nature and extent of the challenges that remain, and the proposed plan to address those, and whether political interference is among the remaining challenges.

The Emfuleni intervention close-out report should likewise indicate progress made on instituting disciplinary processes, where evidence exist, on officials identified to have transgressed the prescripts governing municipalities, including the implementation of the investigation reports indicated during the Portfolio Committee visit.

End.

Reply:

• Hon. Marchesi, both Minister Nxesi and Deputy Minister Moloi were appointed to their portfolios on the 1st of June 2019.
• Former Minister and former Deputy Minister left the Department few weeks before the applicable date of 1st June 2019.
• Having stated the above, kindly find below information relevant to your question.

Office	Financial year	(a) Make	(b) Model	(c) Year Model	(d) Cost	(e) Purchase date
Minister	2019/ 2020	N/A	N/A	N/A	N/A	N/A
	2020/ 2021	N/A	N/A	N/A	N/A	N/A
	2021/ 2022	N/A	N/A	N/A	N/A	N/A
	2022/ 2023	N/A	N/A	N/A	N/A	N/A
Deputy Minister	2019/2020	N/A	N/A	N/A	N/A	N/A
	2020/2021	Audi	Q5 TDI Quattro S Line	2020	R 748 353.50	18 October 2021
	2021/ 2022	N/A	N/A	N/A	N/A	N/A
	2022/ 2023	N/A	N/A	N/A	N/A	N/A

Reply:

a) The total number of-

(i) As per the HPCSA register, a total of 16 964 doctors have been trained in the Republic since 01 January 2013.

(ii) As per the SA Nursing Council register, a total of 181 277 Nurses (all categories) have been trained in the Republic since 1 January 2013.

(iii) A total of 5 877 specialists have registered with the Health Professions Council of South Africa (HPCSA) after training in different fields of Specialty in the Republic since 1 January 2013.

b) Of the above trained numbers, the following have been absorbed in the Public Health Sector

(i) Doctors appointed since January 2013 in Public Health Sector is 15 606,

(ii) Nurses (all categories) appointed since January 2013 in Public Health Sector is 52 542 and

(iii) Medical Specialist appointed since January 2013 in the Public Health Sector is 4 293.

 

END.

Reply:

Find here: REPLY

Reply:

The efficacy of the South African National Defence Force (SANDF) deployment in the Cape Flats or anywhere else it is deployed is always under constant review as the situation  evolves, with force levels up scaling or downscaling, or even withdrawal of forces, as the  situation demands. The deployment of the SANDF on the Cape Flats must be regarded as part of the support provided to the South African Police Services as requested and mandated by the President of the Republic of South Africa.

However, the question of whether the deployment has reduced crime in the Cape Flats is best answered by the SAPS and through monitoring and evaluation, which fall outside the ambit of the defense establishment.

Reply:

Question 1

What are the details of the (a) destination and (b) total costs for (i) accommodation, (ii) travel and (iii) any other costs incurred for international travel of each (aa) Minister and (bb) Deputy Minister of his department since 1 June 2019;

Minister

Office Minister	(a)) Destination	(b)Total cost	(i)International accommodation	(ii) travel Flight International	(iii)insurance & fees
Financial Year
2019-2020	Cuba (HAVANA) Côte Divoire (ABIDJAN) Switzerland (GENEVA) Brazil (BRASILIA) Switzerland (ZURICH) Cuba (HAVANA) Côte Divoire (ABIDJAN) France (PARIS (CDG))	R575 017.70		R 559 196.06	Fees: R15 758.64 Insurance: R 6 300.00
2020-2021	NIL	NIL	NIL	NIL	NIL
2021-2022	Switzerland (GENEVA) Côte Divoire (ABIDJAN) Côte Divoire (ABIDJAN) Botswana (KASANE)	R189 395.34	R87 372.34	R98 900.46	Fees: R3 116.14 Insurance: R640.00
2022-2023	Brazil (BRASILIA) Switzerland (GENEVA) Côte Divoire (ABIDJAN) Indonesia (DENPASAR-BALI) Indonesia (Jimbaran) Switzerland (GENEVA)	R481 813.53	R87 372.34	R385 738.00	Fees: R7 468.19 Insurance: R1 235.00
Total		R1, 246 226.57

Deputy Minister

Office Minister	(a) Destination	(b)Total cost	(i)International accommodation	(ii) travel Flight International	(iii)insurance, fees
Financial Year
2019-2020	NIL	NIL	NIL	NIL	NIL
2020-2021	NIL	NIL	NIL	NIL	NIL
2021-2022	NIL	NIL	NIL	NIL	NIL
2022-2023	Spain (BARCELONA) DRC (KINSHASA) Spain (MADRID)	R146 861.31		R142 870.58	Fees: R3 983:88 Insurance: R685
Total		R146 861.31

Question 2

(2) what is the total cost incurred for domestic air travel for each (a) Minister and (b) Deputy Minister of his department since 1 June 2019? NW189E

Minister	a) Total cost for Domestic air travel
Financial Year
2019-2020	R375 383.82
2020-2021	R30 875.68
2021-2022	R327 218.01
2022-2023	R369 300.90
Total	R1, 102 778.41

Deputy Minister

Deputy Minister Minister	a) Total cost for Domestic air travel
Financial Year
2019-2020	R73 623.84
2020-2021	R29 381.05
2021-2022	R109 480.94
2022-2023	R206 634.58
Total	R419 120.41

Reply:

a) The KwaZulu-Natal Department of Human Settlement has advised that all flood victims have been moved from mass care centres and municipal halls. The Department has identified 15 land parcels that are at various stages of planning to build houses for the flood victims.

Property Description	Ward No.	Region	Developmental stage
1.Erf 3213 Reservoir Hills	23	West	Detailed planning
2.Erf 1765 Shallcross Extension 1	17	West	Detailed planning
3.Erf 4519 Reservoir Hills	23	West	Detailed planning
4.Erf 165 Shallcross	17	West	Detailed planning
5.Erven 253-2589 Edgely (Ntshongweni)	7	West	Detailed planning
6.Erf 113 Burlington Heights	65	West	Detailed planning
7.Erf 4687 Kwandengezi A	TBC	West	Detailed planning
8. Portion 21 of Farm Uitkoms & Doornug No.852	5	West	Detailed planning
9.Rem of Ptn 97 of the Farm Klaarwater No.951	17	West	Detailed planning
10.Rem of Ptn 63 of Farm Langefontein No.5981	9	West	Detailed planning
11.Rem of Ptn 2139 Cotton Lands	58	West	Detailed planning
12.Erf 1615 Ntuzuma A	38	West	Detailed planning

b) The movement of flood victims from municipal halls commenced from October 2022 to 24 December 2022

c) The challenges experienced included the following;

1. Finding suitable land for development.
2. Undertaking feasibility studies.
3. Land development planning and approval.
4. Slow pace of constructing Temporary Residential Units (TRUs).
5. Business forums like Delangokubona, that have a negative impact on service delivery.
6. Theft of material on-site.
7. Councillors obstructing relocation by:

• (i) Refusing the import of communities into their wards,
• (ii) Refusing the relocation of flood victims outside their wards
• (iii) Communities not being accommodative to flood victims who are relocated to their neighbourhoods.

Reply:

Yes, I have been informed that there is one ambulance based in Keimoes, however, an ambulance that is based in Kakamas also responds to Keimoes when needed. It must be noted that these are remote areas with low population density and low call out rates.

END.

Reply:

a) The intervention measures are coordinated at local facility level, supported by the District and Provincial administration. During the NEHAWU led strike, the clinical leadership at each facility put in place mechanisms to reduce the impact, including some staff volunteering to work longer hours, some staff performing duties not normally allocated to them e.g. feeding of patients, cleaning the wards. This included a real-time system of diverting emergencies to health facilities that were not or were less severely affected by the strike activities.

The intervention measures also included the National Department of Health led by the Minister, Provincial Departments of Health led by the MEC’s and senior officials in providing support at facility level. The National Health Council also ensure that a coordinated strategy is developed and implemented to support local facility management including monitoring and managing the strike. In selected instances, assistance was sought and received from South African Military Health Services for the most hard hit hospitals.

b) So far, only six (6) deaths are alleged to be attributed to the strike. However, these are subject to ongoing investigation.

END.

Reply:

Yes, the Minister of Cooperative Governance and Traditional Affairs supported Ditsobotla Local Municipality (DLM) in accordance with section 154 of the Constitution by deploying, through the Municipal Infrastructure Support Agent (MISA), four professionally registered built environment practitioners that include two Civil Engineers to support DLM, together with other municipalities within Ngaka Modiri District Municipality (NMDM), in accordance with the District Development Model (DDM). These professionals provide technical support to DLM for infrastructure development throughout the project life cycle from inception, planning, design development, implementation, operations and maintenance that includes roads repairs and refurbishments. Furthermore, DLM was allocated R41 395 000 (R41,395 million) of the Municipal Infrastructure Grant (MIG) that is administered by the Department of Cooperative Governance (DCOG) in the 2022-23 financial year. The MISA deployed professionals provide DLM with both MIG programme support as well as respective MIG funded projects support. The MISA professionals are currently supporting DLM with the implementation of a MIG funded road network upgrading project of R 23 278 513.44 in Blydeville which is in Ward 4. The project is scheduled to be completed in the next financial year. The deployed MISA professionals are supporting DLM to prioritise and plan roads repair projects to be implemented by the North-West Province Department of Public Works and Roads (NWPDPWR) after the signing of a Memorandum of understanding (MOU) on 14 November 2022 between NWPDPWR and DLM. The MOU aims to assist DLM by NWPDPWR with repairing and maintenance of municipal roads. The MOU will be reviewed after a year.

Ditsobotla Local Municipality has been experiencing perennial governance and administration challenges resulting in its failure to fulfil its constitutional obligations including sustainable service delivery. The North-West Provincial Executive Council resultantly intervened by invoking Section 139 of the Constitution which is currently in place. DCOG is monitoring the provincial executive intervention. Section 139 (7) of the Constitution provides, among other things, that if the provincial executive does not adequately exercise the powers or perform the functions the national executive must then intervene.

End.

Reply:

1. In accordance with the data as received from the Health Professions Council of South Africa (HPCSA), the following is the total number of

(a) General practitioners (i) nationally and (ii) in each province:

		PRACTICE_FIELD
REGISTER_NAME	PROVINCE	MEDICAL PRACTITIONER	MEDICAL PRACTITIONER - Restricted Practice	Grand Total
MEDICAL PRACTITIONER	Eastern Cape	2,513	24	2,537
	ex SWA	45		45
	Foreign	473	1	474
	Free State	1,186	18	1,204
	Gauteng	9,669	41	9,710
	Kwa Zulu Natal	5,582	21	5,603
	Limpopo	1,480	23	1,503
	Mpumalanga	1,457	25	1,482
	North West	1,076	23	1,099
	Northern Cape	610	36	646
	UNKNOWN	2		2
	Western Cape	5,939	5	5,944
	Province n/a	383	2	385
MEDICAL PRACTITIONER Total		30,415	219	30,634

 

(b) Specialist medical personnel (i) nationally and (ii) in each province:

Grand totals for all Specialities and all Sub-subspecialties

		PRACTICE_FIELD
REGISTER_NAME	PROVINCE	SPECIALIST	SUBSPECIALIST	Grand Total
MEDICAL PRACTITIONER	Eastern Cape	797	80	877
	ex SWA	37	1	38
	Foreign	344	27	371
	Free State	634	70	704
	Gauteng	5,534	853	6,387
	Kwa Zulu Natal	2,415	348	2,763
	Limpopo	259	14	273
	Mpumalanga	330	9	339
	North West	267	18	285
	Northern Cape	139	9	148
	UNKNOWN	2	1	3
	Western Cape	3,698	625	4,323
	Province n/a	162	25	187
MEDICAL PRACTITIONER Total		14,618	2,080	16,698

(c) Surgeons and (d) Paediatricians (i) nationally and (ii) in each province; -

		S P E C I A L I T Y
REGISTER_NAME	PROVINCE	NEURO- SURGERY	PAEDIATRICS	PAEDIATRIC SURGERY	SURGERY	Grand Total
MEDICAL PRACTITIONER	Eastern Cape	12	87	5	73	177
	ex SWA	1	3			4
	Foreign	2	27	1	15	45
	Free State	13	64	4	47	128
	Gauteng	107	575	27	404	1,113
	Kwa Zulu Natal	41	279	11	245	576
	Limpopo	5	44		15	64
	Mpumalanga	7	28		22	57
	North West	5	25		14	44
	Northern Cape	2	15		7	24
	UNKNOWN				1	1
	Western Cape	59	402	15	281	757
	Province n/a	3	15		13	31
MEDICAL PRACTITIONER Total		257	1,564	63	1,137	3,021

2. The current population for the Country is 60 604 087 as at March 2023. The table below provide the ratio breakdown per occupational category to the population.

Occupational Category Sum - count Total per 10 000 population General Practitioners 30634 5.054774606 Specialist medical personnel 16 698 2.755259723 Surgeons 1 394 0.230017490 Paediatricians 1 627 0.268463742

3. The table below provide a breakdown of (a) doctors, and (c) psychologists who registered with the Health Professions Council of South Africa (HPCSA) since 1 January 2013

NB (b) Nurses do not register with the HPCSA.

Doctors

			PRACTICE_FIELD
REGISTER_NAME	ORIGIN	CAT_FROM_ YEAR	General Practitioners	SPECIALIST	SUB SPECIALIST	Grand Total
MEDICAL PRACTITIONER	SOUTH AFRICAN	2013	1,249	486	77	1,812
		2014	1,244	497	100	1,841
		2015	1,344	670	94	2,108
		2016	1,333	700	72	2,105
		2017	1,105	541	99	1,745
		2018	1,418	519	87	2,024
		2019	1,528	583	73	2,184
		2020	1,583	423	95	2,101
		2021	1,874	625	83	2,582
		2022	2,339	654	83	3,076
		2023	1,947	179	26	2,152
	SOUTH AFRICAN Total		16,964	5,877	889	23,730
MEDICAL PRACTITIONER Total			16,964	5,877	889	23,730

	psychologists	CAT_FROM_YR
REGISTER_NAME	PRACTICE_FIELD	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Grand Total
PSYCHOLOGIST	CLINICAL PSYCHOLOGY	113	101	150	156	114	108	116	134	73	102	50	1,217
	COMMUNITY SERVICE CLINICAL PSYCHOLOGY	87	155	146	118	108	124	119	74	99	99	50	1,179
	COUNSELLING PSYCHOLOGY	47	51	49	41	52	65	67	54	63	63	9	561
	EDUCATIONAL PSYCHOLOGY	51	70	47	62	62	74	54	48	73	67	22	630
	INDUSTRIAL PSYCHOLOGY	98	116	125	127	121	89	115	95	125	88	15	1,114
	NEUROPSYCHOLOGY								59	30	36	4	129
	RESEARCH PSYCHOLOGY	19	13	25	20	18	7	11	8	8	14	1	144
	(blank)	38	1										39
PSYCHOLOGIST Total		453	507	542	524	475	467	482	472	471	469	151	5,013

END.

Reply:

As a result of the process and procedure that must be followed and finished before the final regulation can come into effect, the Department of Military Veterans is working tirelessly to ensure that the military veterans pensions benefit can be paid out, but there is no precise date as to when the military veterans' pension will be paid until all due processes are completed.

Reply:

1. The Chief of Logistics registered and approved the project to build a perimeter fence around the training area because it falls under his responsibility, but it was unable to be executed due to lack of funding.

2. The project will be carried out depending on the availability of funds after it was unable to be executed owing to financial restrictions.

3. The SANDF is currently not involved in any collaborative anti-poaching efforts in the area with other departments due to roles and functions as well as boundary management.

Reply:

a) The relocation of Denel, the state-owned armaments manufacturing institution, necessitates the participation of the entire government, especially the Department of Public Enterprises, under which it falls, as well as National Treasury. The Ministry of Defence and Military Veterans cannot execute this process on their own; they must also be satisfied that there is due diligence prior to relocation. There will also be legal ramifications from the relocation.

b) The deadlines cannot yet be defined because they are dependent on the fulfillment of the conditions outlined in the preceding paragraph. (a).

Reply:

1. (a) See below the breakdown on the expenditure for the diesel consumption by the generators in each province:

Annexure A is attached and it covers a breakdown expenditure for diesel usage by generators for each hospital in the Republic.

b) Yes, the generators are in a workable condition.

2. I will not be making a statement on this matter.

END.

Reply:

National Skills Authority is not an entity of the Department of Employment and Labour. This entity resides in the other sister department. We can therefore reply to your question by stating what is in our purview, the total number of registered persons that have been registered in terms of the Electrical Installation Regulations of the Occupational Health and Safety Act, Act 85 of 1993, as amended, since 1 January 2015 is 8512. They are registered in the following categories:

Electrical Testers for Single Phase: 2814

Installation Electricians: 5387

Master Installation Electricians: 311

Reply:

1. Unemployment Insurance Fund

a) (i) The Unemployment Insurance Fund is headed by a Commissioner. The position of the Commissioner is on a salary level 15, which is equivalent to a Deputy Director-General.

(ii) The Commissioner is supported by four Chief Directors who are appointed on a salary level 14.

b) The Commissioner and the Chief Directors do not receive payment for attending Unemployment Insurance Fund’s meetings.

2. Compensation Fund

a) (i) The Chief Executive Officer (Compensation Commissioner) of the Compensation Fund is equivalent to the Deputy Director-General salary, which is at salary level 15 and,

(ii) Top Executive positions which are Chief Directors in the Compensation Fund are equivalent to Chief Director salary, which is at salary level 14. For the financial year 2021/22 and 2022/23 there are 6 Chief Director positions.

b) Compensation Fund is a schedule 3A entity of the Department of Employment and Labour and the conditions of appointment including remuneration are derived from (or linked to) the salaries and conditions of service which apply to Senior Management positions (SMS) in the Public Service as per DPSA salary scales. The CF SMS members do not get paid to attend meetings.

3. National Economic Development and Labour Council (NEDLAC)

(a) In respect of Nedlac,

• For the 2021/22 financial year the annual salary for the (i) chief executive offer, called Executive Director was R 2 257 687,45.
• for the 2022/23 financial year, the annual salary for (i) the chief executive officer, called Executive Director is R 2 400 624,89.

(ii) The annual salary for the top executive positions for the:

• 2021/22 financial year was as follows:
  • CFO: R 1 917 900,00;
  • Executive Manager: Programmes: R 1 501 529,63;
  • Senior Manager: Corporate Services: R 1 049 271,47.
• 2022/23 financial year is as follows:
  • Chief Financial Officer: R 2 039 444, 42;
  • Executive Manager: Programmes: R 1 596 859,37l and
  • Senior Manager: Corporate Services: R 1 116 127,04.

(b) There is no payment for meeting attendance of executives.

4. ProductivitySA

The salary cost for Productivity SA is as follows:

a) (i) The Chief Executive Officer’s salary was as follows:

2021/22: R 1,773,770

2022/23: R 1,849,160

(b) (ii) The consolidated salary of Executive Managers was as follows:

2021/22: R 9,801,636 (7 Executive Managers)

2022/23: R 10,974,535 (8 Executive Managers)

c) The Chief Executive Officer and Executive Managers do not receive meeting attendance fees.

5. Commission for Conciliation, Mediation and Arbitration (CCMA)

Name of the Entity	Question (a) (i) What (a) is the salary of each (i) chief executive officer	Financial Year (2021/2022)	Financial Year (2022/2023)
CCMA	Chief Executive Officer( Director)	4 222 667.70	4 336 560.85
	CCMA Director (Acting)	45 160.38	N/A
	Question (a) (ii)	Financial Year (2021/2022)	Financial Year (2022/2023)
CCMA	National Senior Commissioner	2 896 550.92	1 013 660.36
	National Senior Commissioner (Acting)	66 050.24	172 976.12
	Executive Governance and Strategy	2 706 573.99	2 686 758.44
	Executive Governance and Strategy (Acting)	N/A	49 022.77
	Chief Financial Officer	2 706 706.85	1 481 078.23
	Chief Financial Officer (Acting)	N/A	126 920.02
	Chief Audit Executive	2 827 986.32	2 813 587.48
	Question (b) -total amount does each get paid to attend a meeting	Financial Year (2021/2022)	Financial Year (2022/2023)
CCMA	Chief Executive Officer( Director)	N/A	N/A
	CCMA Director (Acting)	N/A	N/A
	National Senior Commissioner	N/A	N/A
	National Senior Commissioner (Acting)	N/A	N/A
	Executive Governance and Strategy	N/A	N/A
	Executive Governance and Strategy (Acting)	The Chief Executive Officer and Executive Managers do not receive meeting attendance fees.
	Chief Financial Officer
	Chief Financial Officer (Acting)
	Chief Audit Executive

Reply:

The department through the National Disaster Management Centre (NDMC) is coordinating and collaborating with relevant stakeholders focusing on emergency preparedness to enable a state of readiness by relevant organs of state in anticipation of disasters. In case of the floods, the following key intervention measures were taken by my department: 

• Collaboration with the South African Weather Service (SAWS) in the further dissemination of early-warnings and advisories to relevant organs of state, stakeholders and organs of state for informed decision-making as well as ensuring that further damages and losses are avoided where possible;
• Activation of the National Joint Floods Coordination Committee (NJFCC) as well as facilitate activations of relevant structures across the spheres of government for the coordination of collaborative efforts by all relevant stakeholders regarding response and recovery efforts in affected provinces;
• FacilitateS the deployment of search and rescue teams from the Security Cluster for search and rescue missions in support of the affected provinces;
• Technical support to municipalities through the Municipal Infrastructure Agent (MISA) in addressing some of the critical infrastructure;
• Coordinate relevant national organs of state to mobilise resources and support to respective counterparts through existing sectoral arrangements and programmes;
• Ongoing monitoring of the conditions on the ground and providing support where required to prevent the situation from deteriorating further;
• Classification of the occurrence as a national disaster by the NDMC as per Section 23 of the Disaster Management Act, 57 of 2022 (DMA). This was with the primary objective of strengthening the coordination and management of the occurrence as well as the mobilisation of resources for intervention measures.   
• Declaration of a national state of disaster by the Minister of CoGTA as per Section 27 of the DMA. This was mainly to augment existing legislation and contingency arrangements of the affected organs of state as well as activate other extraordinary measures as and when required.
• Facilitated the development of Seasonal Contingency Plan for the Summer Season by organs of state to deal with seasonal climate and weather-related events based on the Weather Outlook issued by SAWS. The NDMC further developed the National Seasonal Contingency Plan for the Summer Season outlining the preparedness/readiness measures by respective organs of state to deal with flooding eventualities during the Summer Season.
• Furthermore, the National Seasonal Contingency Plan for the Summer Season provides details of the preparedness and response procedures and activation protocols to be followed at national level to respond to disasters. 

End.

Reply:

Yes, I have been informed that Warmsand in the Northern Cape is a farmstead located approximately 20 kilometres from Keimoes and is therefore serviced from Keimoes when required. Patients from all surrounding areas including Eenduin, Friersdale and Warmsand are being served from Keimoes and not Upington as mentioned in the report. There is an Emergency Medical Services (EMS) station in Keimoes that services Warmsand area.

Due to shortage of staff, the service regressed because of the national measles campaign conducted throughout the province. The mobile clinic with the support from Keimoes Community Health Centre (CHC) staff will resume the services with effect from the 1st week of April 2023 in Warmsand and the surrounding areas.

END.

Reply:

1. The department is not aware of “historical concerns with regard to the influence of Mr Bill Gates over the South African healthcare system”. The Bill & Melinda Gates Foundation is one of many philanthropic organisations that contribute to healthcare across the globe. The Foundation “provides funding to organizations to achieve measurable impact in the fight against poverty, disease, and inequity around the world”, and “funds entrepreneurs, companies, and other organizations to create incentives that harness the power of private enterprise to create change for those who need it most.”

The Gates Foundation supports several programs in South Africa with its major focus on health. During the period 2009-2022, the Gates Foundation invested approximately $907 million dollars in South Africa to some 764 grantees and vendors (which include NGOs, universities, science councils, implementing partners, and manufacturers).

With specific reference to the vaccine programmes during COVID-19, departments and/or entities to which funds and/or donations were sent and/or directed by, include only one government entity, the SAMRC for the Sisonke healthcare worker COVID 19 vaccination programme, plus several private and non-government organisations.

With specific reference to SAHPRA since 1 January 2009 the Gates Foundation direct support to SAHPRA is $7.6million to date.

2. The Foundation has provided no direct funding to the NDoH since 1 January 2009 to date. The focus of the Foundation’s health investments is related to TB and HIV response and span the spectrum from discovery, translation science, product development and delivery of new interventions.

https://www.gatesfoundation.org/about/committed-grants?country=South%20Africa&region=AFRICA]

According to the Foundation the programmes and/or associations envisaged through the funding of the Foundation, include:

(i) in the current year:

• Technical Support to the TB Programme
• Technical Support on HIV quality improvement and HIV Prevention
• Technical support to the DDG NHI
• Catalytic support for scale up evidence-based TB and HIV interventions in South Africa
• SAHPRA was supported with paying for external reviewers (both South Africa and non-South African) selected by SAHPRA to address the large backlog (+/- 16000 applications) inherited from the MCC at the request of the SAHPRA Board. This included all products as the Gates Foundation support of external reviewers was not product specific
• Africa Resource Centre to provide technical assistance on Supply Chain management

(ii) envisaged for a later period:

• Provision of catalytic support to implement evidence-based TB and HIV interventions in South Africa

• Support to SAHPRA for digitisation of clinical trials records

END.

Reply:

I have no power to take steps to ensure that the Independent Electoral Commission obtains a seat on the Municipal Demarcation Board. The Board consists of no fewer than seven and no more than 10 members appointed by the President in accordance with section 8 of the Local Government: Municipal Demarcation Act No. 27 of 1998 (“the Act”). The Act also requires the selection panel to consider all applications and from amongst the applicants compile a list of nominees which must then be submitted to the Minister, whereafter the President must make the required number of appointments from the list.

End.

Reply:

1) The arrangement to get the medication from Cuba came into being when the country was faced with a crisis of COVID 19 and the whole country was in a state of disaster. The AGSA's findings indicated that the Department of Defence (DOD) did not follow procurement processes. The DOD then recorded the Rm33.4 as irregular expenditure due to AGSA's findings. The return of the medication back to Cuba came out of a court order which the department had to comply with.

2) There was no misrepresentation of facts, on the matter, the Department had always recorded the irregularity in the financial records as irregular expenditure.

3) (a) The irregular expenditure will be treated as per the irregular expenditure framework prescribed by National Treasury.
(b) The process indicated above will determine the outcome.

(c) There are no further relevant details surrounding the matter.

Reply:

The DOD has a Memorandum of Cooperation (MOC) with Central Energy Fund (CEF) which was signed by the Sec Def (Accounting Officer) as the Head of the Department in 2019.

The DOD is in the process of concluding a new Service Level Agreement (SLA) with Petro SA, which is a subsidiary of CEF, for the supply and delivery of fuel.

Reply:

1. I have directed the Director General of Health to meet with ESKOM to jointly seek interventions to mitigate against loadshedding. The first engagement took place on 22 September 2022. The meetings with Eskom are happening on a regular basis to seek for more exemptions of healthcare facilities. There are further ongoing engagements with both COGTA and various municipalities regarding additional exemptions for both private and public health care facilities from the grid.

2. No.

END.

Reply:

1. The Tembisa Hospital matter is still under investigation by the Special Investigating Unit (SIU). Once the investigation has been finalized, the Department will comply with any directives issued by the SIU. If such directives includes the blacklisting of the companies referred to, the Department will implement the recommendation.

2. (a) and (b) - No Department within the Public Health Sector have blacklisted any company since 01 January 2020 to date.

END.

Reply:

The honourable member should be aware that the Department of Employment and Labour is not the custodian of the production of official labour statistics in the country. The Quarterly Labour Force Survey (QLFS) and the Quarterly Employment Survey (QES) are quarterly produced by Statistics South Africa (StatsSA) and contain information on labour statistics.

However, the Department extracts and analyses labour statistics but the information is limited to what has been published. The total number of jobs that have been lost in the Republic by industry are provided and known but the survey questionnaires used by StatsSA does not cover the cause of jobs lost by industry.

In this context, there is probably no direct correlation between the ongoing energy crisis and the total number of jobs that have been lost using both survey data.

To the extent, researchers have reported a number of factors that could explain slow economic growth and low absorption rate in the country. These factors include electricity-load shedding, low investment, low savings, low international demand (low volume of exports) etc.

Reply:

a) The ARMSCOR Board of Directors currently has three (3) vacant positions. The Ministry and ARMSCOR intend to ·fill these vacant positions as soon as possible, but no later than the conclusion of the first quarter of the current fiscal year, which begins  on April 1, 2023.

b) Following the completion and upgrading of the job profiles, the senior vacant positions in the Department of Defence, namely the Secretary for Defence and Chief Financial Officer (CFO), will be posted.

Other senior positions in the Department of Defence, including Chief Defence Material (C Def Mat), Chief Director(ate) International Affairs (COIA), Chief Director(ate) Legal Services (COLS), and Chief Audit Executive (GAE), were submitted to DPSA, but there was disagreement about rank levels. The Department of Defense is working with the DPSA on the topic.

Furthermore, the senior empty jobs in the Department of Military Veterans have been re-advertised because the period in which they were advertised had since lapsed without any acceptable candidates being selected .

Reply:

Through the office of the Deputy Minister which played a significant role in encouraging and supporting families to report to the South African Police Services (SAPS) to open criminal cases against Izincibi and Amakhankatha who have kidnapped and taken the under-age children to Initiation school without parental concert and permission.

According to the information at the disposal of the Department, received from the Provinces by the National House of Traditional and Khoi-San Leaders (NHTKL), through the South African Police Services (SAPS) and the National Prosecution Authority (NPA) from the year 2012 to 2018, there were two hundred and forty (240) arrests in relation to initiation related casualties.

The Honourable member is requested to note that according to section 31(1) of the Customary Initiation Act, 2021 (Act No. 2 of 2021) principals of initiation schools concerned are responsible for reporting the deaths of initiates.

In this regard, section 31 of the Act provides that if an initiate dies while attending an initiation school, the principal of such school must immediately inform among others, the South African Police Service.

End

 

Reply:

Curriculum reform and review, by its very nature is dynamic and cyclical. The Department has a long history of reviewing and amending curriculum based on the needs, independent research and monitoring and evaluation findings to ensure relevance and improved learning outcomes. The Departmental approach to curriculum review is ongoing and needs based. For example, since the implementation of the CAPS curriculum in 2012, the DBE has introduced new subjects, such as 9 new technology subjects and Marine Sciences. We are currently also piloting 13 new vocationally and/or occupationally orientated subjects in the GET phase ( Grade 8 and 9)  as part of our ongoing review of curriculum in order to improve learning outcomes. The Three Stream Model, that we are currently implementing, is also a result of ongoing monitoring and efforts to improve the quality of learning outcomes. The additional learning pathways will ensure that we provide our learners with multiple opportunities to transition successfully from school to life after school. 

In keeping with the pursuit of improving the quality learning outcomes, the Department of Basic Education is in the process of reviewing and strengthening the curriculum, to equip learners with skills and competencies for the future. These efforts will continue to focus on the improvement of learning as the end result of schooling. To achieve this lofty goal, the DBE is reviewing the current curriculum, to strengthen it and align it to realise the full implementation of the Three-Stream Curriculum Model. 

The key levers of the review, will  focus on the curriculum;  teaching; assessment; learning and teaching support materials (LTSM), and the learning environment. Due to the centrality of curriculum to ignite the other key levers, the DBE is focusing on strengthening the curriculum at this stage, with a focus on -

• Infusing competencies in the curriculum; 
• Review and modernise existing curriculum content; and 
• Subject modernisation

To realise the curriculum strengthening, the DBE is currently developing the South African Competency Framework, which will prioritise the key competencies (knowledge, skills, attitudes and values) to develop in our learners to equip them with skills for the future. As part of this review, the DBE will also develop a curriculum review policy framework, to ensure regular and faster curriculum renewal. The strengthened curriculum will include in its design, opportunities for continuous automatic renewal to stay abreast with the fast changing world. 

At the same time, work is continuing in the areas of reviewing our assessment practices, teacher development and LTSM to ensure we improve learning outcomes sustainably. 

Reply:

(a) I have been informed by the Department that the total number of small, medium and micro enterprises (SMMEs) that were supported by the Department to exhibit in Meetings Africa 2023 were Eighteen (18).

(b) Participation and exhibition cost of R1 065 552,95 has been paid by the Department.

The Department is awaiting final invoices for the approved flights and accommodation of supported enterprises, as well as outstanding claims from some of the supported enterprises for costs incurred on ground transport and shuttle services.

Thus the total estimated cost of support for the 18 enterprises that participated at Meetings Africa 2023 is not finalised.

 

Reply:

The total number of George Local Municipality workers who have gone through disciplinary proceedings, quit their jobs, or been fired since Dr. Michelle Gratz's appointment is not known to the department.

End.

Reply:

The 3898 schools on the SAFE programme have not been provided with appropriate sanitation facilities by 31 March 2022.

a) The Provincial Departments made several changes to the list.  This may be due to the rationalisation of small & unviable schools, or due to further detailed assessments. The initial number of school assessed to be dependent on BASIC pit toilets, was 3 898.  This number has been amended as more detailed information became available.  Some schools were removed from the list, and other schools were added to the list.  Even in 2022 and 2023, new schools were added to the SAFE Initiative.  After revision, the current number of schools on the SAFE programme is 3 397.

b) Of these 3 397 schools, sanitation projects at 2 489 schools have already progressed to Practical Completion with either water-borne or dry sanitation solutions; resulting in 908 schools remaining in the SAFE programme.

c) A list of the 908 schools can be made available.

d) The outstanding 908 sanitation projects are scheduled for completion during the 2023/24 financial year.

e) All the schools that were part of the 3 397 schools, that were part of the SAFE programme, had BASIC PIT TOILETS.  As stated above, some of these schools received flush toilets (where there is sustainable water supply), and dry sanitation solution |(where there is water scarcity).

(i) Among the remaining 908 SAFE projects, schools with sustainable water supply, may receive flush toilets; and schools without a sustainable water supply, will in general receive VENTILATED IMPROVED PIT TOILETS, that conform to the requirements of SANS 10400 Q.  We are working with the Water Research Commission to pilot other innovative technologies, which included closed-circuit flush toilets.

(ii) Average construction cost per school, is in the order of R2.4 million, including VAT, the demolition of basic pit toilets, all earthworks, building works, and the construction of walkways and retaining walls.

Reply:

I have been informed that neither the Department nor the SA Tourism has had any communication or engagements with the Airports Company (ACSA) or the various airlines to limit the price increases.

The issue of pricing lies solely with the airlines, in conjunction with ACSA.

Reply:

Yes. If the Minister receives concerns about the appointment of municipal officials, section 106 of the Municipal Systems Act, 2000, as amended, (the Act) empowers the Minister to refer the concerns to the MEC for local government under whose jurisdiction the municipality falls for investigation and to make appropriate recommendations to the relevant municipal council.

a) nNotwithstanding the above, section 57A of the Act empowers the Minister to maintain a record of all staff members dismissed for misconduct and to make such record available to municipalities before they finalise their recruitment and selection proceses. Candidates shortlisted by municipalities are screened against the record kept by the Minister.

Sections 54A(8) and 56(6) of the Act prescribe that if a person is appointed as municipal manager or manager directly accountable to municipal manager in contravention of the Act, the MEC must within 14 days of receiving the appointment report take appropriate steps to enforce compliance by the municipal council with the Act, which steps may include an application to a court for a declaratory order on the validity of the contract, or any other legal action against the municipal council.The Act empowers the Minister upon becoming aware to take such appropriate steps if the MEC fails to take appropriate steps.

b) N/A.

End.

Reply:

I am currently seeking legal advice on matters relating to the South African Tourism Board, which includes all appointments and the processes that were followed.

 

Reply:

(a) I have been informed that the Department’s Green Tourism Incentive Programme assists in mitigating the impact of loadshedding on the tourism industry. The main objective of the GTIP is to encourage tourism establishments to adopt more energy and water efficient operational practices to ensure long term sustainability.

(b) The Department is not mandated to deal with the fuel shortage, but does engage with the industry as and when needed. The issue of fuel shortages is dealt with by relevant institutions i.e. Airports Company South Africa, Department of Transport and Airlines Association of Southern Africa. It is recommended that the member refer the above question to the above institutions.

(c) The Department’s Tourism and Climate Change Response Programme and Action Plan, developed in 2011, addresses both climate change mitigation and adaptation measures within the tourism sector.

The Response Programme and Action Plan were designed to deliver on the following five (5) outcomes:

• Improved understanding of the vulnerabilities of tourism to the physical impacts of climate change in order to build resilience and adaptive capacity of the industry;
• Reduced Tourism-related greenhouse gas emissions;
• A fully informed tourism industry through consistent and effective industry outreach and communications;
• A nationally consistent, inclusive and cooperative approach to implementation; and
• Maintain effective climate change messaging and positioning in our key markets.

Reply:

The coronation of a King or Queen is the competence of the Royal Family concerned and government participates based on the invitation from the relevant Royal Family. At this point, the Department has not been informed of the coronation that the Honourable Member is referring to nor do we have any further details to that effect.

End

Reply:

(1) and (2)

I have discussed the matter with the Minister in the Presidency responsible for BrandSA.

It appears that there was no Cabinet decision on the matter as it had never served in Cabinet.

Furthermore, consultations with affected and interested parties had not been concluded.

 

Reply:

(a) I have been informed that the previous Tourism Transformation Council of South Africa (TTCSA) expired on 30 June 2022.

(b)

This process ensued before I took office.

However, I have been informed that after the closing date, the Department embarked on process to capture the nominations and to recommend a selection committee to make recommendations on the suitability of candidates for appointment.

It then came to light that some nominations may have not been successfully delivered to the Department because the email system of the Department went down during the period when the call for nomination was open.

The failure of the email system on the process for the submission of nomination was investigated. It was found that the GroupWise database of the Department got corrupted and prevented the delivery of some emails to the Department.

The email outages towards the closing date of the nominations and subsequent loss of emails was found to have impacted negatively on the nomination process for new members of the TTCSA.

It was evident some nominations could not have reached the Department which would then render the nominations process unfair, unless nominations were opened again to remedy the situation.

Approval to start a new process to call for nominations was granted on 9 September 2022.

(c)

Following approval to re-advertise calls for the nominations of new TTCSA members, the Department of Tourism sent adverts in the main newspapers with national coverage detailing the requirements, and the closing date for nominations was 30 November 2022.

The matter was not concluded by the previous Minister. I have not been consulted by the Department on the new process

(d)

I am informed that before the end of the previous Council’s term in June 2022, the TTCSA, in partnership with the Department of Tourism, appointed a service provider to conduct an annual survey to measure the extent of transformation in the tourism sector across all the three tourism sub-subsectors, namely (1) Accommodation; (2) Travel and (3) Hospitality as well as covering all nine provinces.

The Department established the Tourism B-BBEE Sector Transformation Directorate, which also serves as a Secretariat to the TTCSA. The directorate continued with the research work to gauge transformation levels in the sector.

(e)

I have been informed that the Department conducted policy advocacy presentations on the Amended Tourism B-BBEE Sector Code to various tourism stakeholders in various provinces to create and broaden awareness.

Reply:

Following the adoption of the District Development Model (DDM), the Department of Traditional Affairs developed a guideline on the participation of Local Houses of Traditional and Khoi-San Leaders in the DDM. The Department continues to use the guideline to support and promote the role of traditional leaders in the DDM. Secondly, the Department of Traditional Affairs and the National House of Traditional and Khoi-San Leaders (NHTKL) are finalizing a Memorandum of Understanding with the South African Local Government Association (SALGA) which will assist in strengthening and harmonizing relations between traditional leadership and municipalities. This is one of the resolutions taken at the Local Government Summit that was held last year.

Furthermore, Section 81 of the Municipal Structures Act has been amended to provide greater clarity on the participation of traditional leaders in municipal governance. Before the amendment, concerns were raised, among others, about the lack of specific provisions that would guide provinces to ensure effective implementation. Finally, the Department has also put in place Guidelines on the participation of traditional leadership in municipal lntegrated Development Planning) IDP processes, and these provide a simplified uniform approach for involving traditional councils in the planning processes of municipalities.

End.

Reply:

The Portfolio Committee on Cooperative Governance and Traditional Affairs convened a meeting with the City of Ekurhuleni on the 2nd September 2022, to engage the Executive and Senior management on petitions, amongst which the matter of refuse removal was discussed. The Metro indicated their constraints (financial and tools of trade) towards sufficiently servicing communities on refuse removal, amongst other services. In response, a medium to long-term mitigation plan was tabled to remedy the situation, which would have been shared with the Portfolio committee.

Based on the details provided in the foregoing engagement, the nature and extent of these challenges generally, particularly refuse removal, there is no trigger for a Constitutional “intervention”. However, further to the mitigation plan that the City tabled, both National and provincial governments continue to implement the provisions of Section 154 of the Constitution, in the form of a Gauteng ‘Local Government Support Framework’ anchored around Multi-Disciplinary Regional Support Teams (inclusive of Sector Departments) and implementation of Regional Support Plans. This plan is monitored on an ongoing basis and reported to Cabinet as part of the State of Local Government report (SOLG) and the Portfolio Committee. End.

Reply:

1. Yes, the South African government participates annually in the United Nations Permanent Forum on Indigenous Issues (UNPFII) through representation by the Departments of Traditional Affairs and International Relations and Cooperation respectively. The implementation of the United Nations Declaration on Indigenous Peoples is a standing agenda item at the UN Permanent Forum which takes place every year. South Africa played a central role in the establishment of the United Nations Permanent Forum on Indigenous Issues (UNPFII) which came into existence on 28 July 2000, and a leading role in the negotiations of the United Nations Declaration on Indigenous Peoples (UNDRIP), a process that took 27 years and that culminated in the adoption of the Declaration in 2007.

The UNDRIP is considered the most comprehensive international instrument on the rights of indigenous peoples. It establishes a universal framework of minimum standards for the survival, dignity, and well-being of indigenous peoples. It further elaborates on existing human rights instruments and clarifies how they apply to the specific situations of indigenous peoples. However, the Declaration is a non-binding text, meaning that the Member States of the United Nations are not obligated to implement the declaration. Nonetheless, South Africa as a democratic State observes, protects, and promotes the rights of all the citizens including the Khoi and San.

2. Yes, South Africa participated in the high-level plenary meeting of the General Assembly known as the World Conference on Indigenous Peoples held in 2014, which was attended by the Heads of State and government ministers. The main agreement was for States to take concrete action to achieve the ends of the UN Declaration on the Rights of Indigenous Peoples.

End

Reply:

(b) I have been informed that the organisation has an annual budget for all Board expenses, inclusive of Board Fees and Travel and Accommodation expenditure. Budgets are not allocated per meeting. The breakdown of responses for questions (a), (c) and (d) are tabulated, below.

(i) 2020-2021

(a) What are the dates on which the board meetings of SA Tourism Boards were held	(c) What was the expenditure for each board meeting	(d) What are the details of each expenditure item for each board meeting that was held:
		Board remuneration/Board Fees	Travel and Accommodation
15 April 2020	R27 888.00	R27 888.00	N/A – Virtual Meeting
20 April 2020	R25 269.00	R25 269.00	N/A – Virtual Meeting
21 April 2020	R30 507.00	R30 507.00	N/A – Virtual Meeting
24 April 2020	R20 031.00	R20 031.00	N/A – Virtual Meeting
28 April 2020	R17 412.00	R17 412.00	N/A – Virtual Meeting
30 April 2020	R30 507.00	R30 507.00	N/A – Virtual Meeting
05 May 2020	R27 888.00	R27 888.00	N/A – Virtual Meeting
07 May 2020	R30 507.00	R30 507.00	N/A – Virtual Meeting
14 May 2020	R27 888.00	R27 888.00	N/A – Virtual Meeting
26/30 June 2020	R30 507.00	R30 507.00	N/A – Virtual Meeting
08 July 2020	R30 507.00	R30 507.00	N/A – Virtual Meeting
06 August 2020	R30 507.00	R30 507.00	N/A – Virtual Meeting
19 August 2020	R25 269.00	R25 269.00	N/A – Virtual Meeting
22 September 2020	R25 269.00	R25 269.00	N/A – Virtual Meeting
30 September 2020	R22 650.00	R22 650.00	N/A – Virtual Meeting
22/23 October 2020	R30 507.00	R30 507.00	N/A – Virtual Meeting
7 December 2020	R27 888.00	R27 888.00	N/A – Virtual Meeting
29 January 2021	R25 269.00	R25 269.00	N/A – Virtual Meeting
02 February 2021	R22 650.00	R22 650.00	N/A – Virtual Meeting
31 March 2021	R30 507.00	R30 507.00	N/A – Virtual Meeting

(i) 2021-2022

(a) What are the dates on which the board meetings of SA Tourism Boards were held	(c) What was the expenditure for each board meeting	(d) What are the details of each expenditure item for each board meeting that was held:
		Board remuneration/Board Fees	Travel and Accommodation
29 April 2021	R34 824.00	R34 824.00	N/A – Virtual Meeting
28 May 2021	R29 586.00	R29 586.00	N/A – Virtual Meeting
29 July 2021	R30 507.00	R30 507.00	N/A – Virtual Meeting
19 August 2021	R27 888.00	R27 888.00	N/A – Virtual Meeting
03 September 2021	R17 412.00	R17 412.00	N/A – Virtual Meeting
15 September 2021	R27 888.00	R27 888.00	N/A – Virtual Meeting
22 September 2021	R25 269.00	R25 269.00	N/A – Virtual Meeting
04 October 2021	R33 126.00	R33 126.00	N/A – Virtual Meeting
22 &23 October 2021	R77 694.8	R53157	R24 537.80
28 October 2021	R27 888.00	R27 888.00	N/A – Virtual Meeting
10 November 2021	R27 888.00	R27 888.00	N/A – Virtual Meeting
22 November 2021	R25 269.00	R25 269.00	N/A – Virtual Meeting
27 November 2021	R27 888.00	R27 888.00	N/A – Virtual Meeting
14 December 2021	R20 031.00	R20 031.00	N/A – Virtual Meeting
27 January 2022	R81018,95	R30507.00	R50 511. 95

(i) 2022-2023

(a) What are the dates on which the board meetings of SA Tourism Boards were held	(c) What was the expenditure for each board meeting	(d) What are the details of each expenditure item for each board meeting that was held:
		Board remuneration/Board Fees	Travel and Accommodation
25 April 2022	R30 507.00	R30 507.00	Virtual meeting
27 May 2022	R30 507.00	R30 507.00	Virtual Meeting
29 July 2022	R0	R0	No Board (ACEO appointed as the Accounting Authority)
13-16 September 2022	R190633,51	R45300	R145333,51
21 September 2022	R22650	R22650	Virtual meeting
23 September 2022	R25269	R25269	Virtual Meeting
26-28 September 2022	R337757,66	R50538	R287 219.66
3 October 2022	R17412	R17412	Virtual Meeting
27 October 2022	R73453,81	R27888.00	R45 565.81
04 November 2022	R58 661.74	R27888.00	R30 773.74
19-20 November 2022	R176 094.00	R61014	R115 080.00
25 November 2022	R23809	R23809	Virtual Meeting
01 December 2022	R47902,85	R27888.00	R20014.85
03 December 2022	R27888.00	R27888.00	Virtual Meeting
22 December 2022	R20 031.00	R20 031.00	Virtual Meeting

(ii) Since 1 January 2023

(a) What are the dates on which the board meetings of SA Tourism Boards were held	(c) What was the expenditure for each board meeting	(d) What are the details of each expenditure item for each board meeting that was held:
		Board remuneration/Board Fees	Travel and Accommodation
16 January 2023	R20031	R20031	Virtual Meeting
27 January 2023	R94167	R43656	R50 511.95
31 January 2023	R24526	R24526	Virtual meeting
4 February 2023	R32620	R32620	Hybrid – No travelling members
5 February 2023	R32620	R32620	Hybrid – No travelling members
10 February 2023	R32620	R32620	Hybrid – No travelling members
16 February 2023	R32620	R32620	Hybrid – No travelling members
26 February 2023	R23332	R23332	Virtual Meeting
1 March 2023	R79158,32	R26030	R53128.32

Reply:

(a),(b) Public Protector recommended that the matter be referred to court. The Department of Agriculture, Land Reform and Rural Development implemented Public Protector’s remedial actions by referring the matter to court under case number LCC15/2020.

 

END